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Gene delivery vectors that restrict the expression of therapeutic genes to a 
particular type of cells are critical to gene therapy in a complex structure, such 
as the central nervous system. Therefore, the development of targeted gene 
delivery to diseased subtypes of neurons will benefit the success of gene 
therapy for neurological disorders. In this study, chimeric polypeptides were 
constructed for targeted gene transfer to cells expressing nerve growth factor 
(NGF) receptor TrkA. 
Firstly, a recombinant polypeptide composed of a targeting moiety derived 
from loop 4-containing hairpin motif of NGF and a DNA-binding moiety of 10-
lysine sequence was expressed in E. coli. The recombinant cationic 
polypeptide facilitated gene delivery to PC12 cells that express the NGF 
receptors. It activated NGF receptor, TrkA and its downstream signaling 
pathway in PC12 and promoted the survival of neuronally differentiated PC12 
cells deprived of serum. The polypeptide could also bind plasmid DNA and 
enhance polycation-mediated gene delivery in NGF receptor-expressing 
PC12 cells, but not in COS7 cells lacking NGF receptors. The enhancement 
of gene transfer in PC12 was inhibited by pretreatment of free, unbound 
polypeptides, suggesting a NGF-receptor-specific effect of the polypeptide. 
These pilot observations demonstrated the concept of using receptor-
mediated mechanism for targeted gene delivery to neurons.  
To eliminate the effect of the bulky fusion protein in the recombinant 





targeting moiety derived from NGF loop 4 and the DNA binding moiety of 10 
lysine residues was employed for more systemic study. This peptide activated 
signal transduction pathways of the NGF receptor TrkA in PC12 cells and 
supported the survival of the cells after serum deprivation with better 
efficiency. After forming complexes with plasmid DNA, the peptide dose-
dependently increased reporter gene expression in PC12 cells, which could 
be inhibited by excess NGF. The peptide-mediated gene expression was not 
affected in PC12 cells by co-incubation with a blocking antibody against the 
low affinity NGF receptor p75NTR and was significantly enhanced in NIH3T3 
cells stably transfected with TrkA cDNA, suggesting the involvement of the 
high affinity NGF receptor TrkA without the participation of p75NTR. The 
peptide-mediated gene expression in rat primary cortical neurons was 
localized mainly in those expressing TrkA and hardly seen in the cells stained 
positively with anti-TrkB or TrkC antibodies. Moreover, the peptide did not 
assist gene transfer in TrkA-poor, but TrkB- and/or TrkC-positive primary 
cerebellar granule neurons and primary cortex glial cells. The present study 
demonstrated as well that the peptide enhanced polyethylenimine (PEI)-
mediated in vivo gene transduction in rat dorsal root ganglia, a site with TrkA-
expressing neurons.  
In summary, the chimeric polypeptides reported would be useful in gene 
delivery to and gene therapy of the nervous system and other tissues/organs 















1.1 Gene Therapy 
1.1.1 Background of Gene Therapy 
As early as 1963, J. Lederberg addressed the concept of gene therapy in 
an article "Biological Future of Man" (Wolff and Lederberg, 1994): 
“We might anticipate the in vitro culture of germ cells and such 
manipulations as the interchange of chromosomes and segments. 
The ultimate application of molecular biology would be the direct 
control of nucleotide sequences in human chromosomes, coupled 
with recognition, selection and integration of the desired genes…” 
This represents the earliest statement of manipulation of the human 
genome. Considering this thought was raised far beyond the recombinant 
DNA era, the idea was quite avant-garde. The concept of gene therapy lies in 
the postulation that genetic diseases could be treated by direct correction of 
the genetic defect itself via replacing or supplementing the mutant gene with 
normal and functional genes. The material support for the gene therapy 
concept came from the knowledge of cell transformation by tumor virus. 
These tumor viruses have been so evolved that they could stably introduce 
new genetic information into the mammalian cells, which propose that they 
may also be used to introduce normal genes to correct the genetic defect and 
cure diseases if deprived of their own harmful functions (Friedmann and 




1987). In fact, some of the viruses have been so efficient in transfection that 
they become widely used vectors in gene delivery research.  
However, in the first attempt at human gene therapy, gene delivery was 
performed with a nonviral method. For many years, b-thalassemia had been 
considered as the initial disease target for gene therapy. In 1980, University 
of California at Los Angeles (UCLA) researcher, Dr. Martin Cline performed a 
recombinant DNA transfer into cells of the bone marrow of two patients with 
b-thalassemia without the approval of UCLA Institutional Review Board (IRB). 
In this unsuccessful attempt, cloned human b-globin gene was delivered with 
the use of calcium phosphate-mediated DNA transfer (Mercola et al., 
1980;Cline et al., 1980). However, it was proved later that the regulation of 
hemoglobin synthesis was so complicated, which made b-thalassemia difficult 
to tackle by gene therapy still in its early days.  
In light of Dr. Cline's controversial experiment, the discussions of gene 
therapy focused on the argument of its place in medicine and its ethical 
acceptability rather than its technical issues like efficiency, targeting and 
disease models. It was not until 1989 that the first approved clinical gene 
transfer took place, in which NeoR gene-marked tumor-infiltrating 
lymphocytes (TIL) were transferred into patients with advanced cancer 
(Rosenberg et al., 1990). This first federally approved human genetic 
engineering experiment demonstrated that an exogenous gene, although only 
a marker gene, could be safely transferred into a patient and the gene could 




Michael Blaese and French Anderson from the U.S. National Institutes of 
Health performed the first approved gene therapy procedure on four-year-old 
Ashanti DeSilva with a rare genetic disease called severe combined immune 
deficiency (SCID) (Blaese et al., 1995). The genetic defect of this illness lies 
in the adenosine deaminase (ADA) gene, which leaves the patient extremely 
vulnerable to infection due to the lack of a healthy immune system. In 
Ashanti’s gene therapy protocol, gene-corrected autologous T cells were 
infused intravenously. Laboratory tests have shown that the therapy 
strengthened Ashanti's immune system and she continued to lead a normal 
life. Although this procedure was not a cure, ADA-corrected T cells only work 
for a few months, and the process must be repeated every few months, this 
was the first proof of therapeutic benefit of gene therapy.  
With the revolutionary advance in cellular and molecular biology and 
human genetics in the past two decades, gene therapy has progressed from 
theory to practice within a short period of time. The number of clinical trials in 
gene therapy continues to grow, with as much as 636 clinical trials identified 
and 3500 patients already involved. The diseases addressed include cancers, 
monogenic diseases, infectious diseases, vascular diseases and other 
diseases. The genes transferred include suicide genes and genes encoding 
cytokines, antigens, tumor suppressors, markers and receptors etc. For 
updated information on gene therapy trials worldwide, refer to the website 
http://www.wiley.co.uk/genmed/clinical/. Up to now, gene therapy (somatic) 




However, the same gene transfer technology, with which therapeutic gene is 
delivered to the patient’s cells may also be used for the purpose of functional 
enhancement, which is to “improve” the non-disease traits. In fact, the side 
effects from the present gene therapy protocols seem so minimal that genetic 
engineering for non-disease conditions is about to appear. A well-known 
example was that a US biotechnology company has developed the 
technology for gene transfer into the hair follicle cells and tried to apply it to 
deliver genes to promote hair growth for the treatment of chemotherapy-
induced hair loss in cancer patients (Hoffman, 2000). And of course, the 
application of the technology could be easily adapted to treat the healthy 
balding men. Even though there is no big deal about treating baldness with 
gene therapy itself, the risk-benefit analysis should be taken into account 
while using gene therapy for a broad range of enhancement purposes. Since 
gene therapy is still in its infantile stage, the long-term side effects to patients 
after altering the genetic information are not fully understood, the 
unpredictable dangers caused by gene therapy still exist. Only when enough 
knowledge of the long-term effects are obtained from somatic cell gene 
therapy in the treatment of disease that the technology should be applied for 
the non-disease conditions. Similar but more complicated considerable 
concern exists in germline gene therapy, in which both medical and ethical 
issues are deeply involved and in which sufficient knowledge from both 
somatic gene therapy in human and germline genetic engineering in animals 




Gene therapy holds great promise for treating diseases. But beyond all 
those hypes and discussions, one has to realize that gene therapy, more 
precisely ‘gene therapy research’ has not made noticeable impact on the 
medical practice in the past decades and will not until the full development of 
sophisticated gene delivery systems. As we can imagine, an ideal gene 
delivery vector will be injectable, will target the diseased cells, will transfer 
therapeutic genes efficiently to most of these cells safe and sound, will direct 
the insertion of therapeutic genes into proper region of the genome or just 
stay as stable episomes, will be regulated by either administered agents or by 
normal physiological signals and will be cost-effective to produce. Most 
importantly, it will cure disease. Despite numerous clinical trials have been 
carried out, no notable clinical successes have been shown. Yet, with the 
invaluable knowledge provided by these clinical trials, progresses are being 
made and gene therapy will almost certainly revolutionize the practice of 
medicine in the future and provide an ultimate treatment for a vast range of 
diseases that are plaguing mankind today. 
1.1.2 Gene Delivery with Nonviral Vectors 
1.1.2.1 The importance of gene delivery vectors  
With the completion of the human genome project and the development of 
functional genomics, a greater understanding of the molecular basis of 
genetic disease will render enormous therapeutic genes for the purpose of 
gene therapy. By then, the only hurdle to the application of these information 




systems. Recently, naked DNA has been used for gene transfection into cells 
with the help of physical methods such as electroporation, gene gun, 
ultrasound and hydrodynamic pressure (Niidome and Huang, 2002). Since no 
carrier is involved, this simple method avoids carrier-related issues like 
complex formation and safety. But the drawbacks are also obvious, which 
include no protection of DNA from serum nucleases attack, rapid clearance of 
DNA by mononuclear phagocytes, limited expression level, and no cell 
specificity. Although naked DNA combined with physical methods could be 
used for gene delivery, however, to obtain specificity, targeted vectors are 
necessary. The vectors with cell specificity are the ideal means by which DNA 
molecules are delivered to the target cells. 
1.1.2.2 The viral vectors 
Generally, there are two classes of vectors for gene delivery. The first 
class is known as viral vector (Somia and Verma, 2000). This group of 
vectors is derived from common human viral pathogens. With the use of 
genetic manipulation, these viruses have their genomes modified or “gutted” 
to prevent viral replication, inflammation, cytotoxicity, immunogenicity, and 
permit loading of therapeutic genes. The most commonly used viral vectors 
are derived from retrovirus, lentivirus, adenovirus and adeno-associated virus. 
These viral vectors can deliver gene efficiently into a broad range of cell types 
and are widely used in both basic research and therapeutic application.  
However, there are some inherited limitations that prevent viral vectors to 




Verma, 2000;Williams and Baum, 2003;Dobbelstein, 2003). Although most of 
the deleterious genes have been eliminated from the genomes of these viral 
vectors, unexpected and unpredictable side effects may still exist and the 
safety issue remains a big concern. One major obstacle facing the viral 
vectors is the immune response of the host. The host immune system 
recognizes the viral proteins and eliminates the virus-infected cells by cellular 
immunity, whereas, the strong secondary immune response evoked by 
memory cells rules out the possibility of repeat administration of viral vectors 
(Dai et al., 1995;Kafri et al., 1998). To be “stealthy” in the host, most of the 
viral vectors are designed to have their own proteins synthesis silenced after 
transduction. Meanwhile, to be efficient in transfection, the “gutless” viral 
vectors still need the full complement of viral structure proteins, which may 
elicit the host immune response. In fact, for adenoviral vectors, the immune 
response of the host could become so serious that it might be fatal. The 17-
year-old Jesse Gelsinger was the first patient to die in a Phase I gene therapy 
clinical trial, in whom the death could be directly relevant to the vector-an 
adenoviral vector (Marshall, 1999;Lehrman, 1999;Smaglik, 1999). Gelsinger 
suffered from ornithine transcarbamylase (OTC) deficiency, an inherited liver 
disease that causes life-threatening levels of ammonia to build up in the 
blood. In an attempt to correct this deficiency, a crippled form of adenovirus 
(the second generation of adenoviral vector deleted for the E1 and E4 genes) 
was used to deliver the OTC gene. But instead of curing the disease, it 




inflammatory response." Within hours, Gelsinger's temperature shot up to 
104.5 degrees Fahrenheit. He went into a coma on the second day and was 
put on dialysis and then on a ventilator. His lungs filled with fluid. When it 
became impossible to oxygenate his blood adequately, he died. The tragic 
death of Gelsinger has shocked the whole research community. Many 
questions have been raised about the future of human gene therapy, while 
the safety for patients in gene therapy became the biggest concern.  
Another safety concern in gene therapy using viral vectors is the 
insertional oncogenesis. In a clinical trial, 10 patients with X-linked severe 
combined immunodeficiency (SCID-X1) were transfused with their own gene-
corrected bone marrow-derived progenitors and stem cells. These cells were 
transduced with retroviral vectors carrying the therapeutic gene, which 
encoded the common g chain of the interleukin-2 receptor (gc), a protein that 
is defective in SCID-X1 patient. Nine of the 10 patients showed significant 
long-term improvements in the immune function for this fatal disease (Hacein-
Bey-Abina et al., 2002). However, the two youngest patients have developed 
T cell leukemia due to the insertion of the retroviral vector near the promoter 
of the proto-oncogene LMO2 (Hacein-Bey-Abina et al., 2003). Compared with 
the risk study in animals, the chance of insertional oncogenesis in the 
retrovirus-mediated gene therapy (2 out of 10) was surprisingly high. More 
amazingly, both patients had the retroviral insertion at the same LMO2 gene 
locus, which was unlikely a untargeted and random event. A possible 




product, provided the strong selective advantages to the transducted cells 
and led to the high frequency of insertional mutagenesis and subsequent 
clonal dysregulation.  
1.1.2.3 The nonviral vectors 
The idea of using virus as gene delivery vector is tempting for its simplicity 
in principle and high efficiency, but the challenges are also apparent. To 
overcome the problems plaguing the viral vectors, alternative approaches 
must be explored. In an attempt to create synthetic carriers that have the 
virtues of viral vectors but without their negative attributes, a second class of 
gene delivery vectors referred as nonviral vectors are developed (De Smedt 
et al., 2000;Niidome and Huang, 2002;Davis, 2002;Vijayanathan et al., 
2002;Thomas and Klibanov, 2003). These nonviral vectors include mainly 
cationic lipids and cationic polymers (also known as polycations). With the 
high positive charge density, they function to interact with the negatively 
charged plasmid DNA to form lipid-DNA complexes (lipoplexes) or polycation-
DNA complexes (polyplexes).   
Synthetic nonviral vectors may have some potential advantages over the 
viral counterparts and safety concern further strengthens the need for the 
development of nonviral vectors. Nonviral vector could be non-toxic, non-
pathogenic and non-immunogenic, which allow large-dosage and/or repeated 
administration to achieve the same efficacy of viral vectors. The therapeutic 
gene delivered by nonviral vector could remain episomal and avoid the risk of 




expression of the nonviral vectors could be easily overcome with repeated 
injection. Synthetic vectors may also have large capacity of therapeutic gene, 
which is required for the delivery of either antisense oligonucleotides or 
artificial chromosomes. Also, it is much easier to retarget a nonviral vector to 
a specific cell type than a viral one. The cost and ease of manufacturing has 
also become a real issue for gene delivery vectors. Viral vectors are biological 
agents that can only be made in the living cells. To carry out good 
manufacturing practice (GMP) and quality assurance/quality control (QA/QC) 
procedures in these biological systems is not an easy thing. On the other 
hand, synthetic nonviral vector could avoid the using of the tissues or cells as 
bioreactors, which may simplify the whole manufacturing process. All the 
above characters suggest that synthetic nonviral vectors should be the main 
vectors for routine gene therapy in the future.  
1.1.2.4 The barriers to nonviral gene delivery 
Although nonviral vectors have potential advantages over the viral 
counterparts, it is still early to say which vector will prevail. The problem of 
‘which vectors will prevail’ even exists in the field of nonviral vector itself. For 
cationic lipids, the formation of lipoplexes depends largely on the interaction 
among lipid molecules in addition to lipid-DNA interaction. The hydrophobic 
segments of lipid molecules are the major determinant for the characteristics 
of the resulting lipoplexes, which results in only limited control over the 
parameters like particle size, shape, stability or interactions with cell surface, 




al., 2002b). In contrast, the formation of polyplexes does not require the 
interaction among polycation molecules and polycation-DNA interaction is the 
major driving force. This property leaves greater control over the particle 
characteristics. In addition, the polycations can be easily modified by 
chemical methods to achieve higher efficiency and specificity. The 
polycations also have more flexibility in terms of molecular weight, polymer 
structure and polymer to DNA ratio. With all the properties, polycations seem 
potentially superior to cationic lipids in their pharmaceutical prospective 
(Gebhart and Kabanov, 2001). 
For nonviral vectors, the major challenge is to improve the efficiency of 
gene delivery to a level that surpasses that of viral systems. However, to 
reach such a goal, nonviral vectors need to overcome a series of barriers 
before adequate amounts of therapeutic genes are delivered to the nucleus. 
These barriers may include: 
 (1) The stability of nonviral systems in the extracellular environment: Both 
nonviral vectors and the delivered genes are required to remain intact in 
extracellular space, such as intercellular or intravascular milieu before 
reaching their target cells. The existence of nuclease results in rapid 
degradation of the DNA after their intravenous or intramuscular injection. This 
issue could be partially overcome by the cationic polymers that condense or 
complex with the negatively-charged DNA and therefore resist the nuclease-
related degradation (Li et al., 1999;Adami and Rice, 1999;Yang et al., 2001). 




of the nonviral gene delivery complexes is the increased ionic strength. In a 
high ionic strength environment, the interactions between polycation and DNA 
become weak. Aggregation of the complexes may also happen due to the 
weakened interparticle electrostatic repulsive force. The endogenous 
negatively-charged molecules may also destabilize the nonviral complexes. 
These negatively-charged components like serum albumin, glycoprotein may 
compete with nonviral vectors for DNA binding or facilitate the complex 
aggregation (Oupicky et al., 1999;Ruponen et al., 1999;Wiethoff et al., 2001). 
To deal with complex disintegration, cationic polymers with high charge 
density like polyethyleneimine (PEI) are used (Ruponen et al., 1999). To 
prevent complex aggregation, polyethylene glycol (PEG) molecules are 
attached covalently to provide a steric barrier (Kwok et al., 1999;Hwang and 
Davis, 2001).  
(2) The cellular uptake of nonviral gene delivery systems: The plasma 
membrane forms the first barrier for the transport of gene to the nucleus. 
Since most biological molecules are unable to diffuse through the 
phospholipid bilayers, certain pathways are required for the passage of 
therapeutic gene across the membrane. The attachment of naked DNA to the 
cell surface is the very beginning step in the process of intracellular gene 
transfer. However, it is not a spontaneous one due to the high negative 
charge density of both DNA and cell surface. The positive charges of nonviral 
vector can neutralize the negative charge of DNA and thereby increase the 




(HSPGs) on the cell surface are thought to be one of the molecules that 
mediate the binding and the subsequent internalization of the nonviral gene 
delivery systems (Mislick and Baldeschwieler, 1996). HSPGs are omnipresent 
on all cell surfaces, which not only function in various cellular process, but 
also mediate the entry of several viruses (Bernfield et al., 1999). Experiments 
showed that the presence of HSPGs significantly improved the gene delivery 
by nonviral vectors. Although HSPGs may enhance nonviral gene delivery, 
receptors are the means by which the specificity of gene transfer are fulfilled. 
Another strategy to increase the DNA attachment is the conjugation of 
targeting ligands to nonviral vectors or directly to DNA. Through the 
interaction of cell surface receptors and ligands, the ligand-containing nonviral 
systems may be directed to particular cell types. 
After surface attachment of DNA particles, cells are able to take them up 
by a process known as endocytosis. In this process, the particles are 
surrounded by an area of plasma membrane, which buds off inside the cells 
to internalize the ingested materials. Depending on the targeted cell type and 
receptors as well as the properties of nonviral vector/DNA particles, various 
endocytosis pathways may involve. The most common process is receptor-
mediated endocytosis, in which clathrin-coated pits take part in the 
internalization of nonviral vector/DNA complexes (Friend et al., 1996;Zuhorn 
et al., 2002a). Studies indicate that some clathrin-independent pathway may 
also involve. One of these mechanisms involves the uptake of DNA particle in 




al., 1994;Hofland et al., 2002). Other clathrin-independent processes like 
phagocytosis and macropinocytosis that are common in “professional 
phagocytes”, but rather rare in other cell types, have also been detected in 
nonviral gene delivery to several mammalian cell lines (Francis et al., 
1993;Labat-Moleur et al., 1996;Matsui et al., 1997;Harbottle et al., 1998). It 
seems that all these mechanisms participate with different extent, but for 
efficient nonviral gene delivery, it is really necessary to understand which are 
most important in certain individual cell types. 
(3) The escape of nonviral systems from endosomes: Following the 
internalization, the endocytic vector-containing vesicles fuse with early 
endosomes, which locate in periphery of cytoplasm with an acidic internal pH 
of ~6. The early endosomes function as a sorting compartment, from where 
the internalized materials are redistributed. There are two possible outcomes 
for the internalized materials (Clague and Urbe, 2001). In recycling 
endosomes, the internalized materials are thought to be returned to the cell 
surface. One evidence demonstrating this possibility is that adenovirus with 
deficient endosome-escaping ability has been found to be rapidly internalized 
and at least partially recycled back to the cell surface (Greber et al., 1996). 
Another possible fate for the materials taken up by endocytosis is their 
transportation via late endosomes to lysosomes, in which the endocytosed 
materials are degraded by the action of acid hydrolases (Luzio et al., 2001). It 
is conceivable that similar fates may happen to those nonviral gene delivery 




is no information available on which outcome is more likely for nonviral 
systems, both will obviously reduce their intracellular trafficking to the 
nucleus. Therefore, efficient endosomal escape ability is one of the key 
factors that should be considered for designing efficient nonviral vectors. 
Some of the current existing nonviral vectors may have shown intrinsic 
endosomolytic ability. For cationic lipid vectors, lipid mixing between the 
endosomes and vectors is thought to be the mechanism involved (Xu and 
Szoka, Jr., 1996). It was postulated that the negatively-charged 
phosphatidylserine in endosomal membrane interacts with the cationic lipids, 
which leads to liposome fusion and transgene release. In the case of 
polycation vectors, the exact mechanism involved in endosomal escape is still 
being defined and some hypotheses have been proposed. One of these is 
known as the ‘proton sponge’ hypothesis, which is used to explain the 
endosomolytic ability of polycations with ionizable amine groups (Boussif et 
al., 1995). In early endosomes, the slightly acidic environment is maintained 
by the action of membrane H+ pumps that transport the proton against the 
concentration gradient across the endosomal membrane (Grabe and Oster, 
2001). Polyethylenimine (PEI) is a well-known cationic polymer for its high 
gene transfer efficiency. The unique feature of PEI is its high positive charge 
density with one protonable amino nitrogen in every 3 atoms. Branched PEI 
contains 25, 50 and 25% of primary, secondary and tertiary amines 
respectively and has high buffer capacity over a broad pH range. The 




and under acidic pH in endosomes and lysosomes, the highly branched PEI 
absorbs a large amount of proton ions like sponge. This buffering effect leads 
to the increased influx of H+ into endosomes followed by the influx of Cl- and 
H2O, which causes osmotic swelling and rapture of endosome and thus 
allows the release of transgene into the cytosol. The ‘proton sponge’ 
hypothesis is supported by the fact that ionophore, which reduces the 
transmembrane pH gradient, also reduces the release of PEI/DNA complexes 
and thus inhibits the transgene expression (Kichler et al., 2001). However, the 
‘proton sponge’ ability of PEI and other protonable polymer under 
physiological ionic strength and in the complexation with DNA may change 
significantly, which suggest the necessity of further re-evaluation of the 
hypothesis (Godbey et al., 2000).  
While not all the present nonviral vehicles are effective in endosome-
escape, viruses, however, have developed successful strategy to overcome 
the endosomal membrane. Learning from virus is beneficial to the 
development of the nonviral vectors. The infection process by enveloped 
influenza virus has provided one of the best-known mechanisms for 
endosome-disrupting. The influenza viruses enter the host cells by receptor-
mediated endocytosis. In acidic endosomes, the viral membrane fuses with 
endosomal membranes, followed by the release of genetic materials into the 
cytosol and the initiation of virus replication. The crucial molecule in this 
fusion process is a glycoprotein called hemagglutinin (HA) (Carr et al., 1997). 




and protrudes from the virus surface. In a natural conformation, each HA1 
subunit forms a globular domain at the tip of spike, which may bind to the host 
cell membrane and initiate viral entry. Each HA2 subunit is composed of 4 
domains, which are a N-terminus fusion peptide, a short a-helix, a nonhelical 
loop and a long a-helix. At neutral pH, three long a-helixes from HA2 subunits 
form a three-stranded coiled coil. The whole HA2 subunits are buried within 
the HA1 subunits with each HA2 subunit linked to one HA1 subunit by a 
disulfide bond at the base of the molecule. At low pH in endosomes, the 
fusion proteins are exposed after a series of molecular events. First, the three 
globular HA1 domains separate from each other; second, the nonhelical loop 
region of each HA2 changes into an a-helix and forms a long a-helix together 
with the existing short and long a-helix. These three 88-aa a-helixes form a 
13.5-nm-long three-stranded coiled coil, which protrudes from the viral 
membrane with the fusion peptide exposed at the tip. The insertion of these 
fusion peptides into the endosomal membrane triggers membrane fusion 
process.  
To mimic the endosome-escaping mechanism evolved by viruses, the 
small peptide domains from virus that have crucial function in the fusion 
process are used to equip the nonviral gene delivery systems. One of these is 
the above-mentioned N-terminal fusion peptide from influenza virus HA2 
subunit. This peptide is an amphiphilic anionic peptide, which undergoes 
conformational change in response to the variation in pH (Lear and DeGrado, 




the repulsion of the negatively-charged glutamic acids and aspartic acids. At 
low pH, it transforms into a helical amphipathic structure with hydrophobic 
residues arranged on one side that may interact and destablilize the lipid 
bilayers. Several synthetic amphiphilic peptides have been developed to 
mimic the pH-induced membranes fusion by viral peptide. The synthetic 
peptide GALA containing repeat sequence of glutamic acid-alanine-leucine-
alanine transforms from a random coil at pH 7.5 to an amphipathic a-helix at 
pH 5.0 (Subbarao et al., 1987). With the use of GALA, an increase of 
transfection efficiency of nonviral vectors has been observed (Haensler and 
Szoka, Jr., 1993;Simoes et al., 1998;Simoes et al., 1999). A cationic version 
of GALA, known as KALA was designed for both DNA-compacting and 
endosome-disrupting (Wyman et al., 1997). In transfection in vitro, 
pCMVLuc/KALA complexes produced luciferase activity 100-fold greater than 
that found in the optimal poly-L-lysine/DNA complexes.                
Some pharmacological agents have also been used to enhance DNA 
release form endosomes. Chloroquine, a weak base that accumulates in 
acidic compartments like late endosomes and lysosomes, is commonly used 
to increase the transfection efficiency of nonviral gene delivery systems. 
Possible functions of chloroquine in this process are (i) increasing the 
intralysosomal pH and reducing the degradation by decreasing the hydrolytic 
enzyme activity (Wibo and Poole, 1974;Poole and Ohkuma, 1981;Maxfield, 
1982); (ii) inhibition of endosome/lysosome fusion (Hedin and Thyberg, 




membrane (Zhou and Huang, 1994). All above mechanisms would increase 
the possibility of endosomal escape of transgene.    
(4) The cytosolic transportation: Once escape from endosomes, 
transgenes have to trespass cytosol to reach their final destination - nucleus. 
However, there is no known mechanism for active transport of DNA in 
cytosol. Moreover, the high viscosity of cytosol makes diffusion of transgenes 
in cytosol even difficult. An observation suggests that nucleic acid fragments 
larger than 2000bp are almost immobile in cytoplasm, whereas fragments up 
to 500bp can diffuse freely (Lukacs et al., 2000). The presence of cytosolic 
nucleases may also result in significant degradation of DNA (Lechardeur et 
al., 1999;Pollard et al., 2001). Observations have suggested that in lipoplex-
mediated gene delivery, DNA molecules are set free into the cytosol after 
endosomal escape (Xu and Szoka, Jr., 1996;Cornelis et al., 2002); in polyplex 
systems, DNA molecules are still at least partially complexed with polycations 
(Pollard et al., 1998). Supporting evidence came from the experiments with 
microinjection of both lipoplex and polyplex directly into cytosol. On injection 
of lipoplex, transgene expression is much less than the injection of DNA alone 
(Zabner et al., 1995); in contrast, the microinjection of polyplex results in 
significant transgene expression (Pollard et al., 1998). There is still no clear 
explanation for the enhanced expression of transgenes that are still 
complexed with polycations like PEI or poly-L-lysine. Possible mechanisms 
may lie in the facilitated diffusion due to small size of polyplexes and the 




(5) The nuclear localization: For transgenes to be expressed, they must 
enter the nucleus, in which transcription may take place. Like the cell 
membrane, the nuclear membranes are also lipid bilayers that serve as a 
barrier between the cytoplasm and the nucleus. Transgenes and other 
molecules are unable to diffuse through the nuclear membrane. Unlike the 
cell membrane, no evidence suggests a similar process like endocytosis that 
occurs on the cell membrane can help the transport of materials into the 
nucleus. However, there are still three possible pathways for the nuclear 
localization of the transgenes. DNA can pass through the nuclear pore 
complex (NPC), the only channel for the trafficking of macromolecules 
between the cytoplasm and the nucleus; DNA can enter the nucleus during 
the breakdown and reform of nuclear envelope in mitotic cells; or DNA may 
traverse the nuclear envelope. Of these three possible routes, the second one 
is perhaps quite widespread but with limited application in gene delivery to the 
postmitotic cells; the third seems least likely and has no experimental support. 
The NPC is a large multiprotein structure that spans across the nuclear 
envelop and extends into both cytoplasm and nucleoplasm. In close state, the 
NPC allows passive diffusion of molecules with diameter up to 9 nm (or 
protein up to 50 kDa); during active transport, the NPC permits the passage 
of larger molecules with diameter up to 25 nm (or protein up to 1000 kDa) 
(Mattaj and Englmeier, 1998;Ryan and Wente, 2000). The nuclear import is 
an energy-consuming and carrier-dependent process that may transport 




more special sequences that function as nuclear targeting signal may be 
found (Kalderon et al., 1984;Lanford and Butel, 1984;Robbins et al., 
1991;Siomi and Dreyfuss, 1995). These sequences are designated as 
nuclear localization sequence (NLS). During nuclear transport, free 
cytoplasmic transport factors known as karyopherins associate with the NLS 
of karyophilic protein to form a pore-targeting complex. The complex then 
docks on the cytoplasmic side of NPC followed by translocation through the 
pore in an energy-dependent process that is still not clearly understood. 
Despite the mechanism of trafficking through NPC has not been fully 
understood, researchers have attempted to apply this knowledge in gene 
delivery. One possible way for targeting the DNA to the nucleus is to include 
the binding sites for karyophilic proteins in the transgene sequence. With the 
binding of karyophilic proteins, nuclear transport of transgene may be 
facilitated. SV40 enhancer sequence that can bind to a variety of transcription 
factors has been known to help the DNA nuclear transport (Dean, 1997). For 
more specific nuclear transport, the integration of tissue specific promoter 
sequence that interacts with specific transcription factors in cytoplasm was 
also examined. It has been demonstrated that the incorporation of promoter 
for smooth muscle gamma actin facilitates the plasmid transport to the 
nucleus of smooth muscle (Vacik et al., 1999). Therefore, this strategy may 
not only improve the nuclear transportation of transgene, but also may act in 
a tissue-specific manner. Using this strategy, the design of nonviral vectors 




binding sequence of transcription factors and utilizes the cell machinery 
evolved for nuclear transport of karyophilic proteins, it is not necessary to 
include a nuclear transport mechanism in the vectors themselves. Alternative 
way to facilitate DNA nuclear transport is to conjugate the NLS peptide to the 
transgene. NLS peptide covalently associated with DNA has been proved to 
help transgene nuclear localization (Zanta et al., 1999). The concept has also 
been demonstrated with DNA noncovalently associated with NLS via charge 
interaction or specific peptide nucleic acid (PNA) sequence (Branden et al., 
1999). Despite all these experiments, still no solid evidence proves that the 
conjugated NLS peptides to DNA actually function as nuclear localization 
signal.  
Within all these possible hurdles to nonviral gene delivery, it is hard to say 
which step poses the most difficult barrier. It seems that the relative 
contribution of each step to the overall gene delivery may vary in accordance 
with the targeting cell types. Therefore, to design a versatile vector that is 
suitable for all cell types may not be practical. It will be more likely that the 
nonviral vector should be tailored accordingly for efficient gene delivery to a 
specific tissue. Moreover, to achieve high efficiency, a successful nonviral 
vector should be capable of tackling multiple barriers. To put all these barrier-
tackling modules in one nonviral vector without compromising each other is 




1.1.2.5 The improvement of nonviral vectors 
To achieve effective therapeutic transgene expression, researchers have 
designed nonviral vectors that surmount different obstacles encountered at 
both systemic and cellular levels. Based on the tackling issues, these nonviral 
gene vehicles have been categorized into several groups: (i) the vectors that 
condense and protect DNA and increase complex stability; (ii) the vectors that 
target delivery of DNA to specific cell types; (iii) the vectors for intracellular 
targeting to cytosol or nucleus; (iv) the vectors that can dissociate from DNA 
in cytosol; (v) the vectors that can control DNA release in tissues for 
continuous and controlled expression. Although these vectors are capable to 
overcome certain specific barrier, an ideal nonviral vector that addresses 
multiple barriers still needs to be developed. In general, an ideal nonviral 
vector should have the following basic properties: Condense the DNA into a 
small package; Target specific tissue via cell surface receptors; Avoid 
nonspecific uptake; Escape the endosome; Cross the nuclear membrane.   
Actually, researchers of both viral and nonviral vectors are trying to 
achieve those same objectives from different starts. Viral vectors researchers 
use a ‘top-down’ approach, in which they remove those immunogenic or toxic 
or other noxious components from the viral vectors so that they become safe 
for clinical use. Nonviral vector builders, meanwhile, use a ‘bottom-up’ 
approach, in which components that may improve gene transfer are added 
piece by piece into nonviral gene delivery systems so that they gain the 




predominate in current clinical gene therapy trials because they are efficient 
in foreign genes delivery. These viral vectors have evolved such delicate 
mechanisms to overcome cellular barriers that for them intranuclear delivery 
of foreign gene seems one of the most natural things to do. On the other 
hand, to build a totally synthetic nonviral vector that mimics all those 
sophisticate mechanisms in viral vectors may be difficult. Although we have 
learned a lot from the viruses, the development of safe and efficient gene 
delivery system requires the rational incorporation of these viral strategies 
into a single nonviral vector system, which is still being developed.     
1.1.3 Targeted Gene Therapy 
1.1.3.1 Targeted gene therapy 
The basic criteria of gene therapy were defined long before the 
appearance of any practical applications. It required the therapeutic genes to 
be efficiently delivered to the relevant cells and expressed at appropriate 
level, which implied the necessity of targeted gene therapy. Despite this early 
recognition, the early generations of vectors were designed to provide only 
the basic gene transfer capability without addressing the issue of specificity. 
In viral gene delivery, the cellular uptake was restricted by the native tropism 
of the original virus, whereas in nonviral gene delivery, the uptake was largely 
a nonspecific process. In these researches, the efficiency was listed as the 




In the early beginning, the original idea of retargeting vectors for selective 
gene transfer has been studied only for the purpose of improving the vector 
efficiency itself. The results of early in vivo gene therapy trials have been  
disappointing, which were mainly due to the extremely low rate of cell 
transduction. To improve the gene therapy outcomes, retargeting of vectors 
has been used as one of the strategies to improve vector efficiency. The 
conjugation of ligands to the vectors may increase the attachment of the gene 
delivery complexes to the cell surface. To have high efficiency, ligands to 
those most abundantly expressed receptors were intensively studied.      
In the following studies, it becomes apparent that the lack of targeting 
ability has limited the application of gene therapy to many disease 
candidates. One obvious example comes from cancer gene therapy, in which 
the delivery of toxic genes is one of the most commonly used anti-tumor 
strategies. In this case, the expression of toxic genes should be restricted to 
the tumor cells only, while expression in any other non-tumor cells will be of 
serious consequence. In the context of lack of available vectors with targeting 
ability, to confine both the therapeutic effect and the therapy-related side 
effects, the initial in vivo cancer gene therapy aimed at those localized tumors 
within certain natural body compartments such as glioma, pleural 
mesothelioma and peritoneal carcinomatosis. But even in these space-
confined tumors, ectopic gene delivery still occurred. In this regard, vectors 
without tumor cell targeting ability are apparently not applicable to tumors with 




Similarly, to implement gene therapy to a wide range of disease 
candidates, it is highly desirable that the therapeutic genes are only 
expressed in specific cell types, but not in other cell types. The purpose of 
targeted gene therapy is to restrict the therapeutic effects in only the target 
cells and thus avoid the possible side effects of gene products in the non-
target cells. This is especially important while the target cells are widely 
distributed like cells in hematopoietic system or if the target cells are 
dispersed among highly heterogeneous populations like those in central 
nervous system.  
Nowadays, it is a common recognition that besides safety and efficiency, 
specificity is another very important issue to be considered in developing 
gene delivery systems for gene therapy. The development of cell or tissue-
targeted vectors presents one of the great challenges for gene therapy 
research. 
1.1.3.2 Approaches to targeted gene therapy 
There are three major approaches toward targeted gene therapy. Ex vivo 
therapy is one initial approach used in clinical gene therapy trials. In this 
method, target cells were selected by isolation from the body and modified by 
vector-mediated gene transduction in vitro. The gene-modified cells were then 
transferred back to the body to obtain therapeutic benefit. This procedure was 
often used in treating hematological diseases and diseases of the immune 
system, where the cells could be easily removed and returned. Since cell 




requirement for the targeting ability of vectors, which makes it easier for 
clinical application. In fact, in those human trials with positive findings, ex vivo 
method has been used to treat diseases like X-linked severe combined 
immunodeficiency and hemophilia (Nathwani et al., 2003;Gaspar et al., 2003). 
Unfortunately, only limited diseases are amenable to this ex vivo intervention, 
other strategies for targeted gene therapy are required. 
In clinical application, it is most common that the therapeutic complexes 
are administered to a mixed cell population hoping for the delivery of 
transgene to certain cells. In this scenario, ligand-directed targeting of gene is 
one major approach for targeted gene therapy. Since ligands are able to 
recognize the receptors that are specific for a certain cell type, the addition of 
ligands may bestow the gene delivery vector the ability to distinguish between 
target cells and non-target cells. At present, numerous studies are attempting 
to modify the cell specificity of both viral and nonviral vectors for 
transductional targeting. The third approach for targeted gene therapy is 
based on the modification of therapeutic gene, which is known as 
transcriptional targeting. In this strategy, therapeutic gene is placed under the 
control of cell-specific transcriptional regulatory sequences like promoter, 
enhancer and/or silencer. Since the transcription of therapeutic gene is 
activated only in target cells, the therapeutic effect of gene product is limited 
to the target cells. By combining both transductional and transcriptional 
targeting, it is possible to increase the selectivity at two different levels for the 




1.1.3.3 Targeting of nonviral vectors 
As there is no panacea, there is no versatile vector for gene therapy to all 
kind of diseases. Gene delivery vector has to be customized to fit the 
requirement of various diseases. To target certain diseased cells, a vector 
needs to be modified by integrating ligands that recognize the cell-specific 
receptors. One crucial issue for retargeting the gene delivery systems is to 
reduce the nonspecific attachment to cell surfaces. For current viral systems, 
the biodistribution of vectors is largely determined by the native tropism of the 
parental virus. For viral vector retargeting, it is necessary to reduce the 
binding to native receptors and add a new targeting ligand while keeping the 
efficiency of post-attachment steps in the viral vectors. Similarly, for nonviral 
vector retargeting, although there is no native receptor binding that needs to 
be taken away, it is required to minimize the nonspecific attachment arising 
from the highly positive charge of the cationic vectors. Conceivably, such 
nonspecific interactions may affect or even cover the ligand-directed targeting 
and thus deviate transgene complexes from the target site. Current strategy 
to address this issue has been to shield the vectors with either hydrophilic 
polymers like PEG or with ligand directly (Xu et al., 1999;Kircheis et al., 
2001a;Kircheis et al., 2001b). By masking the surface charge, the intrinsic 
targeting effects could be avoided. This method has been applied to retarget 
both lipid and polymer vectors (Fenske et al., 2001;Kircheis et al., 2001c). 
It should be recognized that the realization of ligand-directed targeted 




novel targeting ligands into the vectors to direct therapeutic gene to new cell 
surface receptors. Depending on the targeted receptors, various ligands have 
been used to conjugate nonviral vectors. Targeted gene delivery has been 
described for a number of cells such as tumors, hepatocytes, epithelium, 
macrophages, lymphocytes and hematopoietic stem cells etc (Anwer et al., 
2003). Ligands tested include galatose, transferrin, folate, mannose, lectins, 
antibodies and receptor-binding peptides (Ziady AG and Davis PB, 2002). 
These ligands include not only endogenous ligands for receptors, but also 
exogenous ligands like antibodies and phage-derived peptides, developed de 
novo. However, there is still a clear appeal to introduce more useful cell-
specific ligands that can be added to the vectors. For many cells of interest to 
gene therapy, suitable cell-specific ligands have yet to be discovered. 
Obviously, to develop efficient targeted gene therapy, it requires not only the 
engineering of functional vectors, but also the introduction of new ligands to 
direct the vectors to the cells of interest. 
1.2 Gene Therapy in the Nervous System 
1.2.1 Gene Therapy in the Nervous System 
1.2.1.1 The appeal to gene therapy in the nervous system 
The neurological disorders have been generally regarded as tragic 
diseases due to their chronic and suffering pathological processes and 
usually poor prognosis. The impairment of the nervous system always 




amyotrophic lateral sclerosis (ALS) may progressively rob control of the body, 
while spinal cord injury may do the same damage in just an instant. 
Alzheimer’s disease (AD) may take away the very essence of one’s 
personality and even life by affecting the cognitive area of the brain and 
eventually the whole brain. These declines in functional abilities impose a 
particularly heavy burden not only to the patients themselves, but also to their 
caregivers and family members as well.    
The disorders of the nervous system have been classified into many 
categories with each of which containing a long list of diseases depending on 
the etiologies, the affected anatomic structures and/or the functional losses. 
They include not only the disorders of higher function, motor control, the 
special senses, spine and spinal cord, body function, but also headache and 
pain, neuromuscular disorders, epilepsy, cerebrovascular disorders, 
neoplastic disorders, autoimmune disorders, disorders of myelin, infections, 
trauma and toxic disorders and degenerative disorders. The detailed 
classification of the nervous system disorders derives from the tradition of 
neurology, which has been focusing on diagnosis with accurate 
neuroanatomical localization of the lesion or pathophysiological definition of 
the disease process. Armed by the powerful neuroimagery technologies like 
X-ray computerized tomography and magnetic resonance imaging, it 
becomes easier for neuroanatomical diagnosis in those structurally based 
conditions; meanwhile, the techniques like pathology, molecular biology, 




the pathophysiological basis of the disorders. However, in contrast to the 
expertise on diagnosis, therapeutic approaches to neurological diseases have 
been very limited.  
The neurological diseases are more common than we might think. For 
example, AD is the most common form of neurodegenerative disease in 
people over 65 years. It is estimated that more than 15 million people are 
affected by the disease worldwide and almost half of those over 85 years 
show signs of the disease (Palmer, 2002). In the United States alone, over 
four million people suffer from AD and another million have PD, the second 
most common neurodegenerative disorder after AD. Since age is the single 
most important risk factor for these degenerative diseases, the number of 
individuals who are developing AD and PD is becoming a considerable 
concern with the increased lifespan of people. Statistics postulate that more 
than 10 million people will suffer from AD in the US by the year 2025, the 
number will approach 20 million by the year 2050. Currently, the estimated 
cost for the care of these AD patients and the lost of productivity in both the 
patients and their caretakers is $200 billion annually in the US (Kawas CH 
and Katzman R, 1999). The number will increase to a more staggering 
amount unless effective means for preventing and/or treating these disorders 
are developed. 
Unfortunately, medical researchers have made only limited progress in the 
battle against the neurological diseases mainly because of the inability of the 




tissues, and the vulnerability of the nervous system to insulting conditions. 
The current neurological treatments are incompetent in preventing the 
relentless loss of neurons, needless to say the perspective of complete 
functional recovery. In the past two decades, significant advance has been 
made in understanding the molecular biology of the nervous system in both 
health and disease (Shilling and Kelsoe, 2002). These advances help to 
uncover the implicating molecules and genes in the nervous system disorders 
and provide the possibility of various new approaches for treating neurological 
diseases such as growth factor therapy, stem cell therapy and immune 
therapy. Particularly, with the substantial advances in understanding the 
pathogenesis of these diseases, new molecular based-therapy like gene 
therapy that delivers the therapeutic gene to the affected nervous system 
offers the possibility to prevent neuron loss and degeneration in the brain, to 
induce new growth and/or even to restore function. 
1.2.1.2 The applicability for gene therapy in the nervous system 
One of the difficulties in treating neurological diseases is presented by the 
anatomical structures such as the cranium, the meninges and the blood-brain 
barrier (BBB) that are protecting the nervous system. The application of 
classical pharmacological treatment is restricted by these structures specific 
to the nervous system, particularly by the BBB. The BBB prevents access to 
the brain of numerous potentially therapeutic molecules, since 98% of all 
small-molecule drugs and 100% of all large molecule drugs do not cross the 




molecules are intracerebral or intracerebroventricular injection or infusion 
using osmotic mini-pump if long-term treatments are required. Even after 
delivery via these routes, the molecules can only penetrate a short distance 
into the brain that limits the therapeutic effect. With intracerebroventricular 
administration, however, the molecules may also diffuse to the sites other 
than the target region via cerebrospinal fluid circulation and cause 
unexpected side effects. Gene therapy provides one possible strategy to 
overcome the limitations of classical pharmacotherapy. This approach uses 
therapeutic gene directly to affect the local and/or focal expression of a 
therapeutic protein to achieve a desired therapeutic effect, therefore offers a 
simple and effective way to delivery therapeutic agents to the brain.  
From the viewpoint of therapeutic strategy, gene therapy is also applicable 
to the neurological diseases. A common pathological event observed in the 
neurological disorders is neuronal death. Although the etiologies may be 
various, the administration of neurotrophic or anti-apoptotic factors presents a 
major strategy for treating such disorders. To maintain the regional 
specialized function of the nervous system, this kind of therapeutic 
intervention should be supplied locally, which may be achieved by therapeutic 
transgene expression. Moreover, the enhanced neurotransmitters synthesis is 
another strategy for treating some neurodegenerative diseases. For example, 
the dopaminergic function needs to be strengthened in PD patients, whereas 
enhanced cholinergic function in AD patients will be beneficial. Obviously, 




the nervous system may share the same neurotransmitter and receptor 
system for signal transduction. In these cases, to avoid the side effects that 
arise from the activation of other pathways sharing the same 
neurotransmitters, it is favorable to achieve the local production of 
neurotransmitters by therapeutic gene expression rather than by using a 
systemically administered drug.   
Therefore, beyond the common disease targets like cancers, monogenic 
diseases, vascular diseases and infectious diseases, the neurological 
disorders are becoming new candidate diseases for gene therapy, 
researchers are now developing different strategies to combat a wide range 
of neurological disorders like neurodegenerative diseases, chronic pain, 
spinal cord injuries or even strokes. 
1.2.2 Targeted Gene Delivery to the Nervous System  
1.2.2.1 The challenges and requirements for gene therapy in the nervous 
system 
There are some characteristics of the nervous system that are challenging 
the development of gene therapy. The nervous system is the most complex 
system in the body. It is estimated that there are about 100 billion neurons in 
human brain that can be functionally classified into thousands of different 
types (McKay, 1989). The synaptic connections among these neurons are 
also complicate. The estimated number of synapse in these neurons is on the 




morphologies and functions; they are delicately organized into distinct 
anatomic structures. These highly organized structures determine not only the 
basic sensory and motor functions but also the higher functions like the 
memory and learning capacities as well as the personality of a person. It is 
conceivable that any changes in the connectivity or activity of neurons may 
cause serious consequences to the patients. Furthermore, the nervous 
system presents the system where most genes are expressed. The neurons, 
the basic units of the nervous system, are post-mitotic and non-dividing cells. 
They have different functions according to their individual patterns of gene 
expression, their anatomical locations and their synaptic connections. To 
make thing more complicate, there are non-neuronal cells in the nervous 
system, which are astrocytes, oligodendrocytes and microglia, with each of 
them performing different functions. Therefore, in such a highly heterologous 
system, it is important to apply therapeutic genes only to target cells during 
gene therapy.  
The neurological diseases tend to affect selective, defined groups of 
neurons with specific biochemical and functional characteristics to produce 
the disease phenotype. For example, the degeneration of dopaminergic 
neurons in the substantia nigra results in the triad of bradykinesia, rigidity and 
tremor in Parkinson’s disease; the degeneration of lower motor neurons in the 
spinal cord and upper motor neurons in the brain results in weakness without 




(MND). Thus, these affected neurons are the primary targeted regions for 
gene therapy in these neurological diseases.    
As previously mentioned, successful gene therapy depends both on safe 
and efficient gene delivery vectors. However, the targeting ability is also 
considered as another important property for a successful vector, which is 
especially crucial for gene therapy in the nervous system. 
1.2.2.2 Targeting of nonviral vectors to the nervous system 
To allow localized delivery of the therapeutic gene and to reduce the 
opportunities of unexpected side effects, cell type-specific gene delivery to 
the neuronal cells is required for the success of in vivo gene therapy of the 
neurological disorders. Among the viral vectors that are commonly used for 
gene delivery, those derived from adeno-associated virus (AAV) infect 
neurons preferentially through the interaction of capsid proteins with HSPG 
moieties on the cell surface (Bartlett et al., 1998); those derived from herpes 
simplex viruses (HSV) show highly efficient retrograde and anterograde 
transport within the nervous system (Chiocca et al., 1990). Obviously, this 
neurotropic property is directed by the native tropism and the viruses can 
infect a broad range of cell types. To generate viral vectors that target one 
specific type of neurons, the envelope proteins that mediate the binding of 
virus to specific receptor need to be genetically modified and this is not an 
easy task. Technically, it would be easier to develop nonviral system for 
targeting a specific group of neurons using novel ligands that bind to the 




nonviral vectors is also necessary to overcome the possible risk associated 
with viral vectors.    
In general, targeted nonviral vector system to neurons is still a field under 
development, which provides only countable publications. In a recent study, 
Peluffo et al used an intergrin-targeting multifunctional protein for gene 
delivery to the central nervous system (Peluffo et al., 2003). This nonviral 
system shows no obvious in vivo toxicity and targets different cell populations 
like neurons, astrocytes, microglia and endothelial cells. In other study using 
bifunctional synthetic peptide, Collins et al synthesized a polylysine-molossin 
peptide that binds integrin for gene delivery into primary cultures of rat 
cerebral cortex neurons (Collins et al., 2003). Apparently, the above systems 
using ligands that bind intergrin, a receptor widely expressed in many cells is 
not suitable for targeting a specific group of neurons. In a better neuronal 
targeting system, one research group used Hc fragment of tetanus toxin as 
targeting ligand to conjugate with polylysine (Knight et al., 1999) or to 
integrate in a multi-domain system for gene delivery to neuronal cell in vitro 
(Box et al., 2003). The research on developing nonviral targeted system for 
gene delivery to a subtype of neurons is also scarce. One group used 
neurotensin as ligand to target the neurotensin receptor expressing in 
neurons like those of the nigrostriatal and mesolimbic dopaminergic systems 
in conjugation with polylysine (Martinez-Fong et al., 1999), the system was 
tested for gene transfer to rat substantia nigra (Alvarez-Maya et al., 2001). 




kinase expressed in both neuroblastoma cells and cells in substantia nigra 
(Yano et al., 2000). Obviously, the above-mentioned vectors may only be 
applied in certain disease conditions. To realize gene therapy in the nervous 
system, various targeted vector systems are still required for specific delivery 
of therapeutic gene to various affected regions in different neurological 
disorders. For targeted gene therapy in the nervous system, nerve growth 
factor (NGF) of neurotrophin family may be a promising targeting ligand in 
nonviral gene delivery system.  
1.2.3 NGF and NGF Peptidomimetics 
1.2.3.1 NGF and its receptors 
Neurotrophins are a family of structurally and functionally related 
homodimeric neurotrophic factors that include NGF, brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), 
and neurotrophin-6 (NT-6) (Barde et al., 1982;Ernfors et al., 1990;Hallbook et 
al., 1991;Gotz et al., 1994). These highly homologous dimeric proteins play 
important roles in the development and maintenance of the peripheral and 
central nervous system (Snider, 1994). Their biological functions are 
mediated through two classes of cell surface receptors: the low affinity p75NTR 
receptor and the high affinity Trk receptors (Chao and Hempstead, 1995;Lee 
et al., 2001). The p75NTR receptor belongs to the tumor necrosis factor 
receptor family and all neurotrophins bind with similar affinities to the p75NTR 
receptor (Kd~10-9 M). The roles of the p75NTR receptor include promotion of 




1996;Casaccia-Bonnefil et al., 1996;Frade et al., 1996;Maliartchouk and 
Saragovi, 1997;Carter and Lewin, 1997;Frade and Barde, 1998;Frade and 
Barde, 1999). The Trk receptors are members of receptor tyrosine kinase 
superfamily, to which the neurotrophins bind selectively with high affinities 
(Kd~10-11M) and act as trophic factors (Cordon-Cardo et al., 1991;Kaplan et 
al., 1991;Soppet et al., 1991;Berkemeier et al., 1991;Klein et al., 1991a;Klein 
et al., 1991b;Ip et al., 1992). Three different Trk receptors are known in 
vertebrates. TrkA is the receptor for NGF; TrkB binds to BDNF and NT-4/5, 
whereas TrkC is the preferred receptor for NT-3. The relationship of 
neurotrophins and their Trk receptors appears somewhat promiscuous. This 
is suggested by the fact that different Trk receptors may bind to the same 
neurotrophin (e.g. NT-3 can also bind to TrkA and TrkB with lower affinity 
than for TrkC.) and that different neurotrophins may bind to the same Trk 
receptor (e.g. BDNF and NT-4/5 may bind to TrkB.).  
NGF, the best-characterized member of the neurotrophin family, was 
discovered half century ago, which promotes the survival of sensory neurons 
in the dorsal root ganglia (DRG) and sympathetic neurons (Levi-Montalcini, 
1987). X-ray crystallography of dimeric NGF revealed a novel tertiary protein 
fold that results in a rather asymmetric molecule (McDonald et al., 1991). 
Each NGF monomer shows a flat and elongated shape with the central part of 
the molecule composed of two pairs of twisted, anti-parallel β-strands. These 
β-strands are connected at one end of the monomer by three hairpin loops, 




cysteine-knot motif that further stabilizes the fold and locks the molecule in its 
conformation. In biologically active form, two NGF monomers are arranged in 
parallel orientation that allows the two pairs of β-strands from each monomer 
to pack against each other and generates a closed-packed homodimer with 
an overall dumbbell-like shape. The two central β-strands (strands A and B 
and strands C and D) of the two monomers assemble to form the ‘handle’ of 
the dumbbell. These four β-strands provide the major interactions that 
stabilize the dimer. On one end of the dumbbell are the cysteine-knot motif, 
the N- and C-termini, and the loop L3 connecting strands B and C, which are 
pointing away from the membrane. On the other end, there are three hairpin 
loops L1, L2 and L4, as well as four short β-strands arranged in two anti-
parallel β sheets. The structures of other neurotrophin family members such 
as BDNF, NT-4/5 and NT-3 have also been revealed, which have shown to 
be structural homologues to NGF (Holland et al., 1994;Robinson et al., 
1995;Butte et al., 1998;Robinson et al., 1999). Sequence alignment analysis 
shows about 50% of sequence identity among the neurotrophins, which maps 
onto strands A, B and D, and loop 3 and many of these conserved residues 
participate in dimer formation (Wiesmann et al., 1999;Wiesmann and de Vos, 
2001). 
The Trk receptors are highly sequence homologous with their extracellular 
portion being classified into five distinct subdomains (Schneider and 
Schweiger, 1991;Kaplan and Stephens, 1994;Patapoutian and Reichardt, 




leucine-rich region (LRR, domain 2), a second cysteine-rich cluster (CR2, 
domain 3), and two immunoglobulin (Ig)-like domains (Ig 1 and Ig 2, domain 4 
and 5). The intracellular tyrosine kinase domain is linked by a putative helical 
membrane-spanning region to the extracellular part. The overall 3-D 
structures of these Trk receptors are still unknown. Functional studies show 
that they may share the common signaling mechanisms. The binding of 
ligand to receptor activates intrinsic tyrosine kinase domains, which catalyzes 
phosphorylation of several tyrosine residues. Following the binding of src 
homology domain 2 (SH2)-containing proteins to these phosphotyrosines, 
three major signaling pathways are switched on (Sofroniew et al., 2001). 
Among these pathways, the Ras/extracellular receptor-activated kinase 
(ERK) and phospholipase Cγ1 (PLC-γ1) signaling are thought to be involved 
in neuronal differentiation and growth by activation of gene expression, 
whereas phosphotidylinositol-3-OH kinase (PI-3K) signaling may promote 
neuronal survival by inhibition of apoptosis. 
In addition to Trk receptors, neurotrophins may also signal through the 
p75NTR receptor. This receptor is a transmembrane glycoprotein. The 
intracellular domain of p75NTR receptor is a death domain that may regulate 
apoptosis and cell death (Bamji et al., 1998), but not a tyrosine kinase domain 
as observed in Trk receptors. The extracellular portion of p75NTR contains four 
cysteine repeat motifs (Smith et al., 1994). The exact role of p75NTR is not 
known. Its biological activity depends on the binding neurotrophins as well as 




1998;Meldolesi et al., 2000). For instance, in the absence of TrkA expression, 
the binding of NGF to p75NTR will result in apoptosis in TrkA-negative cells; in 
the presence of TrkA, p75NTR enhances the binding of NGF to TrkA and 
promotes cell survival (Bamji et al., 1998). 
1.2.3.2 NGF peptidomimetics 
NGF and other members of neurotrophin family have great potential in 
promoting neuronal survival and neurite outgrowth. These polypeptide growth 
factors also have biological functions in several other cell types like lymphoid, 
epithelial, oligoglia and mast cells. Disregulation of neurotrophins or their 
receptors is evident in many human disorders such as Alzheimer’s disease, 
stroke, pain, neuropathy and cancers, in which both hyperactivity and 
hypoactivity of these ligand-receptor systems may be the etiological factors 
(Hefti, 1997;Saragovi and Gehring, 2000). Therefore, neurotrophins and their 
receptors are important therapeutic targets in these diseases (Saragovi et al., 
1999). However, direct applications of neurotrophins are limited, because 
these neurotrophins which have poor stability in vivo may induce unfavorable 
side effects due to their wide array of local and systemic biological activities 
and are expensive to produce (Barinaga, 1994). One approach to address 
these limitations is to develop synthetic, small molecule mimetics of 
neurotrophins with optimal pharmacological profiles (Saragovi and Gehring, 
2000;Massa et al., 2002). The development of agents that act directly at 
neurotrophin receptors as agonists, partial agonists or antagonists is one of 




mimic or disrupt the interaction of the neurotrophins with the extracellular 
portion of Trk (or p75NTR) receptors and be expected to contain structural 
determinants of neurotrophin actions that interact with the receptors. 
Rational design of small mimetics that bind neurotrophin receptors 
requires the understanding of structural basis of neurotrophin-receptor 
interactions. Several strategies have been used to identify the domains in 
neurotrophin that interact with the receptors. In loss-of-function approach, 
individual residues or small domains are deleted or replaced by alanine 
(alanine scanning mutagenesis) or substituted with homologous segments 
from other members of the same family (homologous scanning mutagenesis), 
whereas in gain-of-function studies, chimeric molecules produced by 
exchanging residues or small domains between different members of 
neurotrophin family are prepared. Both the lose-of-function and the gain-of-
function effects in these mutants or chimeric proteins are examined by 
receptor binding as well as biological assays. Moreover, the crystallographic 
studies of the neurotrophins, the fragments of the receptors and the complex 
of neurotrophins and receptor fragments provide further evidence of the 
molecular contacts.  
Various techniques have been applied to discover the domains of NGF 
that interact with its receptors. In a peptide mapping approach that used 
synthetic peptides with sequences corresponding to specific NGF regions to 
inhibit NGF activity, residues 29-35 were identified as a key active site (Longo 




NGF revealed that NGF contained three surface hydrophilic β-hairpin loops 
(loop 1, 2 and 4) that were likely to be the candidate sites for ligand-receptor 
interaction (McDonald et al., 1991;Holland et al., 1994). The previously 
identified residues 29-35 were mapped to loop 1 region of NGF. Studies 
further confirmed that synthetic peptide consisted of residues 25-39 inhibits 
NGF activity and NGF-p75NTR receptor binding (LeSauteur et al., 1995;Van 
der Zee et al., 1996). Recombinant substitution study suggests the 
importance of Lys32 and Lys34 in binding to p75NTR receptors (Ibanez et al., 
1992). Molecular modeling further supports loop1 as critical site for binding to 
p75NTR(Shamovsky et al., 1999). The NGF domains that interact with TrkA 
have also been deduced via different approaches, such as chemical 
modification, recombinant protein and NGF-TrkA-d5 co-crystallization 
(McDonald and Chao, 1995;Woo and Neet, 1996;Kullander et al., 1997;Woo 
et al., 1998;Wiesmann et al., 1999). The above studies indicated that the 
TrkA binding sites primarily consist of residues in NGF loop 2 (residue 40-49), 
loop 4 (residues 91-97) and the N-terminus (residue 1-8).    
In traditional approaches, random screening of chemical compound 
libraries has been used to discover small molecules with receptor binding 
activity. However, these methods are relatively unproductive. An alternative 
approach to identify small molecules that bind neurotrophin receptors is via 
structure-based design (Longo and Mobley, 1996;Cunningham and Wells, 
1997;Kieber-Emmons et al., 1997;McInnes and Sykes, 1997). The sequence 




in defining the specificity of neurotrophins to the receptors. Many synthetic 
peptides mimicking these specific domains of native neurotrophins 
(peptidomimetics) have been shown to function via the neurotrophin 
receptors. These peptidomimetics are often cyclized by intramolecular 
disulfide bond for applying conformational constrain and inducing structure 
more closely matching those corresponding loops in native neurotrophins. In 
an early study, cyclized monomeric peptidomimetic C(92-96) corresponding 
to NGF loop 4 was found to inhibit NGF bioactivity and [125I]NGF binding to 
TrkA-receptor expressing E25 cells (LeSauteur et al., 1995). Subsequent 
NMR studies demonstrated striking similarity between the calculated structure 
of peptidomimetic C(92-96) and the structure of corresponding loop 4 region 
derived from NGF X-ray studies (Beglova et al., 1998). In vivo study showed 
that C(92-96) delivered to rat cortex led to an inhibition of NGF-induced 
upregulation of choline acetyltransferase (ChAT) activity and a decrease in 
the size of cholinergic boutons, suggesting the blocking effect of this 
peptidomimetic to NGF in vivo activity (Debeir et al., 1999). In another design 
of peptidomimetic based on the same NGF loop 4 region, a cyclized dimeric 
rather than monomeric form termed ‘P92’ was synthesized (Xie et al., 2000). 
P92 was found to promote survival and neurite outgrowth of cultured DRG 
sensory neurons with activity well under that of native NGF, suggesting a 
partial agonist profiles. This research also provides substantial evidence 




1.2.3.3 Targeting NGF receptor-expressing neurons 
Obviously, the development of NGF peptidomimetics that bind directly to 
NGF receptors may not only be useful in modulating the biological effects of 
NGF-receptor interaction, but also provide novel targeting ligands for targeted 
gene delivery systems. Using NGF peptidomimetics as targeting ligand may 
overcome those limitations produced by the use of native NGF protein. Also, 
there is apparent necessity for specific gene delivery to those sites with NGF 
receptor, especially to those with TrkA receptor expression. One of the TrkA-
expressing sites locates in basal forebrain, which contains cholinergic 
neurons that are affected in Alzheimer’s disease (AD) (Winkler et al., 1998). 
Widespread neuronal degeneration occurs in AD, which appears to be related 
to the accumulation of a toxic protein, amyloid in the extracellular space in the 
brain. This results in preferential degeneration of cholinergic neurons in the 
basal forebrain as well as structure in the hippocampus and parahippocampal 
gyrus. Targeted delivery of therapeutic genes to these sites has particular 
potential in treating AD. Another site with TrkA-expressing neurons locates in 
dorsal root ganglion (DRG) that contains peripheral sensory neurons (Mu et 
al., 1993;McMahon et al., 1994). Small diameter neurons in DRG are the 
major population with TrkA expression. These neurons are affected in 
sensory polyneuropathy characterized by degeneration of peripheral sensory 
nerve fiber, a common neurological condition for which no current therapies 
exist. Selective delivery of therapeutic gene to these DRG neurons may be 




Outside the nervous system, NGF and NGF receptor expressions have 
been also found in cells of the immune and inflammatory systems (Sofroniew 
et al., 2001;Vega et al., 2003). Several types of leucocytes are known to 
express TrkA, which include mast cells, CD4+ T lymphocytes, B lymphocytes, 
monocytes, and macrophages. Many of these cells also have the capability to 
express NGF. In addition, TrkA receptor expression has been observed in 
various cancer cells (Saragovi and Gehring, 2000). Increased level of TrkA 
expression has been associated with abnormal growth in prostate 
endothelium. Some breast cancer cells have been observed to overexpress 
TrkA. Therefore, NGF peptidomimetic that binds to TrkA may also be used for 
targeted gene delivery to these cells and tissues. 
1.3 Aim of the Study 
The realization of targeted gene therapy for various diseases depends on 
the introduction of different novel targeting ligands into the vectors 
accordingly. These novel ligands would direct therapeutic genes to the 
targeted cell surface receptors. For targeted gene delivery to the nervous 
system, NGF could be a promising ligand, which may target TrkA, a receptor 
expressed in basal forebrain cholinergic neurons that are affected in 
Alzheimer’s diseases. However, to overcome the limitation of using native 
NGF as targeting ligand, smaller and more stable NGF mimetics are 
desirable.  
In this study, a NGF loop 4-containing hairpin motif will be employed as a 




recombinant proteins and chemically synthesized peptides will be used to 
prove the concept. The binding of this hairpin motif to TrkA receptor will be 
examined by biochemical and biological assays. The transfection efficiency 
as well as specificity of these hairpin motif-containing gene delivery vectors 
will be tested by in vitro gene transfer. Toxicity of this novel gene delivery 
vector will also be examined in both in vitro and in vivo studies. This targeted 
system will also be assayed for in vivo gene delivery to TrkA-expressing 
neurons.  
Hopefully, this study will provide an example for using ligand mimetic for 
targeted gene delivery to a subtype of neurons, and also present a platform 
















2.1 Studies Using Bacterially Produced Polypeptides 
2.1.1 Plasmid Construction 
A 29-amino acid sequence derived from NGF loop 4-containing region 
(#80-108) was selected for NGF receptor targeting and designated as NL4. 
The numbering of the amino acid refers to mature NGF (Wiesmann et al., 
1999;Wiesmann and de Vos, 2001). A DNA binding sequence of 10-lysine 
residues was added to the C-terminus of NL4 to form a chimeric peptide NL4-
10K. The DNA sequences encoding NL4 or NL4-10K were PCR-amplified 
from a pcDNA3.1/GS plasmid containing the NGF gene (humFL ORF: H-
X52599M; Invitrogen, Carlsbad, CA, USA), using a common 5’ primer (5’-
TGTACCACGACTCACACC-3’) and 3’ primers (5’-
GCAAGCTTTCAACAGGCCGTATCTATCCG-3’) for NL4 or (5’-
GCAAGCTTTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACAGGCCGTATC
TATCCG-3’) for NL4-10K respectively. These NL4 or NL4-10K encoding 
sequences were inserted in-frame into pET-40b(+) expression plasmid 
(Novagen, Madison, WI, USA) between the ScaI and HindIII sites, 
downstream of the coding sequences for DsbC and a His6 tag. 
2.1.2 Polypeptide Expression, Purification and Detection 
The plasmids were transformed into the E. coli expression host strain 
BL21(DE3)pLysS from Novagen (Madison, WI, USA). A single colony of 
freshly transformed bacteria was suspended in 10ml of LB containing 30 




OD 600 of ~0.6. The cultures were then used to inoculate 400 ml of LB 
medium containing 30 mg/ml of kanamycin and 34 mg/ml chloramphenicol. 
After rapid shaking at 37 °C for 2hr, cells were induced with IPTG and grown 
for another 2hr. The bacteria were harvested and lysed in 20 mM Na2HPO4, 
0.5 M NaCl, 10 mM imidazole, pH 7.4. After sonication and centrifugation, the 
supernatant was purified by nickel-chelating affinity chromatography on an 
ÄKTAexplorer FPLC (Amersham Biosciences, Buckinghamshire, UK). The 
extract was purified on a 1 ml HisTrap column (Amersham Biosciences). 
Elution was carried out with increasing imidazole concentration. The fractions 
containing purified polypeptide were pooled and dialyzed against HEPES-
buffered saline (HBS, 150mM NaCl, 20mM HEPES, pH 7.4) at 4 °C overnight. 
The polypeptides were electrophoresed on 12.5% SDS-PAGE gel and 
transferred to nitrocellulose membranes. An anti-His horseradish peroxidase 
(HRP) conjugates (Qiagen, Hilden, Germany) was used for detection.  
2.1.3 Cell Lines and Reporter Plasmid 
A PC12 (rat pheochromocytoma) cell line was obtained from ATCC 
(American Type Culture Collection, Manassas, VA, USA) and cultured in 
RPMI-1640 medium (National University of Singapore, Singapore) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, 
MO, USA) and 5% horse serum (Sigma-Aldrich, St. Louis, MO, USA). PC12 
cells are known to express TrkA and p75NTR receptors and extensively used 
to study functions of the receptors. A COS7 (African green monkey kidney 




modified Eagle's medium (DMEM) (National University of Singapore, 
Singapore) supplemented with 10% FBS, 50 U/ml penicillin, and 50 mg/ml 
streptomycin. The cells were maintained in a 37 °C, 5% CO2, humidified 
incubator. 
To determine the transfection efficiency of this nucleic acid delivery 
system, a reporter plasmid, pCAGluc (a gift from Yoshiharu Matsuura, 
National Institute of Infectious Diseases, Tokyo, Japan), encoding firefly 
luciferase under the control of the composite promoter, CAG was employed. 
CAG comprises the chicken b-actin promoter and the cytomegalovirus 
immediate early enhancer. 
2.1.4 Detection of TrkA, Erk and Akt Activation  
Immunoblotting experiments were conducted to test whether the chimeric 
polypeptides could, like NGF, induce autophosphorylation of TrkA and 
activate its signal transduction pathways. PC12 cells were seeded in 6-well 
plates at a density of 2x106 cells/well and cultured in RPMI 1640 medium 
containing 0.5% FBS and 0.25% horse serum for 2 days. The low serum 
concentration was necessary to reduce the basal level of phosphorylation. 
The medium was refreshed 2 hr before treatment. The cells were incubated 
with the polypeptides or NGF in serum-free medium for 15-20 min. The cells 
were then washed in phosphate-buffered saline (PBS), lysed, and sonicated. 
The cell lysates were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane for immunoblotting. The primary antibodies used 




(Thr202/Tyr204) monoclonal antibody, and Phospho-Akt (Ser473) monoclonal 
antibody, all obtained from Cell Signaling Technology (Beverly, MA, USA). 
Colorimetric detection was performed according to the Amplified Opti-4CN 
Substrate Kit (Bio-Rad, Hercules, CA, USA) after using HRP-conjugated 
secondary antibodies. 
2.1.5 Cell Survival Assay 
For PC12 survival assay, the cells were seeded in collagen-coated 96-well 
plates in serum-free RPMI 1640 containing 10 ng/ml NGF and cultured for 6 
days. The medium was then changed to serum-free RPMI 1640 containing 
polypeptides at the indicated concentrations. Ten ng/ml of NGF, an optimal 
concentration for PC12 survival, was used as positive control. After incubation 
for 4 days, cell viability was estimated by MTT assay (Promega, Madison, WI, 
USA). Cell survival effects of the polypeptides were expressed as percentage 
of NGF-induced survival.     
2.1.6 DNA Retardation Assay 
This assay qualitatively assesses the ability of polypeptides to bind to 
DNA and thus to retard its migration (by decreasing its charge/mass ratio) 
through an agarose gel under electrophoresis. Plasmid DNA (0.1 mg) was 
mixed by vortexing with polypeptides at various ratios in HBS in a total 
volume of 20 ml. After 30 min incubation at room temperature, the mixtures 
were loaded on a 0.8% agarose gel and electrophoresed at 80 v for 30 min. 




2.1.7 Gene Delivery Assay 
For gene transfection experiments, plasmid DNA/polypeptide/polymer 
ternary complexes were used. To form the complexes, polypeptides and DNA 
were dissolved in OPTI-MEM medium. Equal volume of polypeptide was 
added dropwise to equal volume of DNA while vortexing at desired ratios. 
After incubation for 30 min at room temperature, polyethylenimine (MW ~600 
dal, PEI600) from Sigma-Aldrich (St. Louis, MO, USA) or protamine (Sigma-
Aldrich, St. Louis, MO, USA) diluted in OPTI-MEM was added to the 
complexes to form triple complexes. The required amount of PEI600 was 
calculated by taking into account that 1 µg DNA contains 3 nmol of phosphate 
and that 1 µl of 10 mM PEI600 holds 10 nmol of amine nitrogen. This 
nitrogen/phosphate ratio is defined as N/P ratio and used as a measure of the 
charge balance in a polycation/DNA complex. For the purposes of calculating 
the N/P ratio for the polypeptide used in the study, the number of basic amino 
acid residues in the DNA-binding domain was used as the number of “N” 
moieties per molecule. 
The gene delivery complexes were tested for transfection efficiency in 
vitro in PC12 (TrkA and p75NTR positive) cells and COS7 (NGF receptor 
negative) cells. The cells were grown to 50-70% confluence in microplate 
wells (96- or 24-well plates). DNA complexes were added and incubated with 
cells for 4 hr. The cells were then cultured in normal culture medium for 24 hr 
before luciferase activity assay. After the incubation, cells were washed and 




luciferase activity in cell extracts was measured using a luciferase assay kit 
(Promega, WI, USA). Each measurement was carried out for 10 sec in a 
single-well luminometer (Berthold Lumat LB 9507, Germany). The relative 
light units (RLU) were normalized by the total protein concentration of the cell 
extracts, measured using a protein assay kit (Bio-Rad, Hercules, CA, USA). 
2.2 Studies Using Chemically Synthesized Peptides 
2.2.1 Peptide Design and Synthesis 
The amino acid sequences of NL4 and NL4-10K were previously 
described.  Briefly, a 29-amino acid sequence derived from NGF loop 4-
containing region (#80-108) was selected for NGF receptor targeting and 
designated as NL4. A DNA binding sequence of 10-lysine residue was added 
to the C-terminus of NL4 to form peptide NL4-10K. Both NL4 and NL4-10K 
were prepared using conventional solid phase, chemical synthesis method 
and cyclized by a disulfide bond formed between C80 and C108 by 
Cambridge Research Biochemicals (Cleveland, UK). A 10-lysine peptide 
(designated as 10K) was synthesized by BioSynthesis (Lewisville, Texas, 
USA) as a non-targeted control. All peptides were provided in dry powder and 
stored in –80°C. 
2.2.2 Cell Cultures  
Rat PC12 pheochromocytoma cells that express TrkA and p75NTR 
receptors were also employed in the study using synthetic peptides and 




cell lines, E25 and TRK1, and parental NIH3T3 cells were grown in DMEM 
supplemented with 10% FBS. E25 was developed by Dr. Stuart Decker 
(Parke-Davis Pharmaceuticals) (Decker, 1995), and TRK1 developed by Dr. 
Mariano Barbacid (National Center for Oncological Investigation, Madrid, 
Spain) (Cordon-Cardo et al., 1991), both of which were kindly provided by Dr. 
Alonzo H. Ross (University of Massachusetts Medical School). To maintain 
the expression of TrkA in NIH3T3.E25 and NIH3T3.TRK1, 0.5 mg/ml G418 
(Sigma-Aldrich, St. Louis, MO, USA) or 50 U/ml hygromycin B (Calbiochem, 
La Jolla, CA, USA) was used respectively. The cells were maintained in a 
humidified incubator with 5% CO2 at 37°C. 
Primary cultures of cortical neurons and glial cells were established from 
the cortex of embryonic Wistar rats at gestational day 20. Meninges-free 
cortices were dissected and individual cells were dispersed mechanically by 
trituration of minced tissue in 3 ml DMEM medium supplemented with 2% 
FBS. The suspension was allowed to settle in a centrifuge tube. The cells in 
the supernatant were collected by centrifugation at 1000 rpm for 5 min and re-
suspended gently in DMEM with 10% FBS. Viability of the cells was assessed 
prior to plating using trypan blue. To obtain neurons, cells were plated onto 
microplate pre-coated with poly-L-lysine/laminin at a density of 7.5×105 viable 
cells/cm2. After two-hour incubation to allow neurons to attach, the medium 
and unattached cells were removed and serum-free DMEM/F12 medium with 
1% N2 supplement (Invitrogen, Carlsbad, CA, USA) was added into the plate. 




incubator for 2-5 days before transfection. To obtain glial cells, the cells 
collected from the cortexes were plated at a density of 4 ×105 viable cells/cm2 
on poly-L-lysine/laminin coated dishes and grown to confluence for 7 days in 
DMEM/F12 medium supplemented with 10% FBS. The cells were detached 
and plated into coated plates one day before transfection. 
Primary cultures of rat cerebellar granule neurons were established from 
the cerebellum of 8-day-old Wistar rats. Meninges-free cerebella were 
dissected and individual cells were isolated mechanically by trituration of 
minced tissue in 3 ml DMEM medium supplemented with 10% FBS. Cells 
were diluted with 10 ml DMEM with 10% FBS and let settled in a centrifuge 
tube. The supernatant was collected and centrifuged at 900 rpm for 5 min. 
The pellet was re-suspended gently in DMEM with 10% FBS. Viability of the 
cells was assessed prior to plating using trypan blue. Cells were plated into 
wells pre-coated twice with poly-L-lysine (50 mg/ml) at a density of 7.5×105 
viable cells/cm2. After 2 hr of attachment, the medium and unattached cells 
were removed and serum-free DMEM/F12 medium with 1% N2 supplements 
added afterwards. The cells were then incubated at 37°C in 5% CO2 in a 
humidified atmosphere for 5 days before transfection. 
2.2.3 Biochemical and Biological Assays 
For biochemical assays of TrkA, Erk and Akt activation, PC12 cells were 
seeded in a 6-well plate with the cell density of 2x106/well and cultured in 
RPMI-1640 containing 0.5% fetal calf serum and 0.25% horse serum for 2 




of phosphorylation. After cultured in fresh serum-reduced medium for 2 hr, the 
cells were stimulated for 15 min with 5 μM of NL4, NL4-10K or NL4-10K/DNA 
complexes, and 10 ng/ml of NGF (Invitrogen, Carlsbad, CA, USA) was used 
as positive control. The cell lysates were then prepared and electrophoresed 
on 12.5% SDS gels and transferred to nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK). Membranes were incubated with 
Phospho-TrkA (Tyr490) polyclonal antibody, Phospho-p44/p42 MAPK 
(Thr202/Tyr204) monoclonal antibody or Phospho-Akt (Ser473) monoclonal 
antibody from Cell Signaling Technology (Beverly, MA, USA). Colorimetric 
detection was performed with Amplified Opti-4CN Substrate Kit from Bio-Rad 
(Hercules, CA, USA). To inhibit the tyrosine kinase activity of TrkA, PC12 
cells were pre-incubated with 100 nM K252a (Calbiochem, Ja Jolla, CA, USA) 
and 10 μM AG879 (Calbiochem, Ja Jolla, CA, USA) before addition of 
peptides or NGF. 
For PC12 survival assay, the cells were seeded in collagen-coated 96-well 
plates in serum-free RPMI 1640 containing 10 ng/ml NGF and cultured for 6 
days. The medium was then changed to serum-free RPMI 1640 containing 
NL4 or NL4-10K at the indicated concentrations. 10 ng/ml of NGF, an optimal 
concentration for PC12 survival, was used as positive control. After incubation 
for 4 days, cell viability was estimated by MTT assay (Promega, Madison, WI, 
USA). Cell survival effects of NL4 and NL4-10K were expressed as 




2.2.4 Reporter Plasmid, DNA Binding Assay and Preparation of 
DNA Complexes 
The reporter plasmid encoding firefly luciferase used was pCAGluc (kindly 
donated by Yoshiharu Matsuura, National Institute of Infectious Diseases, 
Tokyo, Japan) with a composite promoter CAG consisting of the CMV IE 
enhancer, chicken b-actin promoter and rabbit b-globin polyadenylation 
signal. Plasmid DNA was amplified in E.coli and purified with HiSpeed 
Plasmid Kit (Qiagen, Hilden, Germany). The quantity and quality of the 
purified plasmid DNA was assessed by optical density at 260 and 280 nm and 
by electrophoresis in 1% agarose gel. The purified plasmid DNA was 
dissolved in TE buffer and kept in aliquots at a concentration of 1 mg/ml. 
For DNA binding assay of the synthetic peptides, plasmid DNA (0.1 μg) 
was mixed by vortexing with NL4-10K or NL4 at various ratios in HBS in a 
total volume of 20 μl. After 30 min incubation at room temperature, the 
mixtures were loaded on 0.8% agarose gel and electrophoresed at 80 v for 30 
min. Gels were visualized under UV after electrophoresis. 
For gene delivery experiments, either plasmid DNA/peptide complexes or 
plasmid DNA/peptide/polymer ternary complexes were prepared with various 
nitrogen/phosphate ratios, which was defined as N/P ratio and used as a 
measure of the charge balance in a polycation or peptide/DNA complex. For 
the purposes of calculating N/P ratio for the peptides used in the study, the 
number of basic amino acid residues in the DNA-binding domain was taken 




DNA was calculated by taking into account that 1 µg DNA contains 3 nmol of 
phosphate. To form DNA/peptide complexes, peptides and DNA were 
dissolved in OPTI-MEM medium (Invitrogen, Carlsbad, CA, USA). Equal 
volume of peptide was added dropwise to equal volume of DNA while 
vortexing at desired ratios. Complexes were incubated for 30 min at room 
temperature before transfection. To form ternary complexes, polyethylenimine 
(MW ~600 dal, PEI600) from Sigma-Aldrich (St. Louis, MO, USA) was diluted 
in OPTI-MEM to contain 10 nmol of amine nitrogen per µl. Equal volume of 
PEI600 was mixed with equal volume of DNA at the indicated ratios while 
vortexing. After 30 min incubation, peptides under testing were added to the 
complexes at ratios indicated to form triple complexes. PEI/DNA complexes 
using a high molecular weight PEI (MW ~25 kDa, PEI25kDa) (Sigma-Aldrich), 
were prepared and used as a positive control in toxicity assays. 
2.2.5 Zeta Potential and Size of the Complexes 
Appropriate amount of a peptide at desired ratios in 250 ml of 5% glucose 
was added in a dropwise manner to 20 mg of DNA in 250 ml of 5% glucose 
while vortexing. After 30 min incubation, the samples were diluted to about 
1.5 ml with 1 mM KCl buffer to ensure that measurements were made under 
conditions of low ionic strength where the surface charge of the particles can 
be accurately measured. The zeta potentials of the complexes were then 
analyzed by phase analysis light scattering using a Brookhaven ZetaPALS 
zeta potential analyzer (Brookhaven Instruments Corporation, USA). Default 




and viscosity were assumed to be the same as for water, and the 
Smoluchowski approximation was used. Determinations were carried out at 
22°C and all buffer solutions used were filtered through a 0.22 mm filter before 
use. For size measurement, the complexes were prepared in the same 
manner as for zeta potential measurement and then diluted to 3 ml with 1 mM 
KCl buffer. Determinations were carried out at 22°C at a fixed angle of 90° by 
dynamic light scattering using a Brookhaven ZetaPALS submicron particle 
size analyzer (Brookhaven Instruments Corporation, USA). 
2.2.6 Gene Transfer 
For in vitro gene transfer, cell culture medium was replaced with OPTI-
MEM before transfection. DNA complexes were added and incubated with 
cells for 4 hr in the presence or absence of 100 μM chloroquine. After the 
incubation in normal culture medium for another 24 hr, cells were washed and 
permeabilized with the reporter cell lysis buffer (Promega, WI, USA). The 
luciferase activity in cell extracts was measured using a luciferase assay kit 
(Promega, WI, USA). Each measurement was carried out for 10 sec in a 
single-well luminometer (Berthold Lumat LB 9507, Germany). The RLU were 
normalized by the total protein concentration of the cell extracts, measured 
with a protein assay kit (Bio-Rad, Hercules, CA, USA). 
For in vivo study, adult male Wistar rats (8 weeks of age, 180-200 g) were 
used. The spinal cord injection procedure was performed under anesthesia by 
peritoneal injection of sodium pentobarbital (60 mg/kg). After the skin around 




syringe connected with 26-gauge needle. A slight movement of the tail 
indicated the proper injection into the subarachnoid space. Three mg DNA/60 
ml of triple complexes were injected into each rat. The injection was carried 
out over 2-5 min and the syringe was left in place for a further 5 min to limit 
diffusion of the complexes from the injection site due to the backflow 
pressure. The skin was closed with surgical clips after the injection. The 
animals were kept warm until recovered. 
Three days after the injection, animals were perfused transcardially with 
0.1 M PBS (200 ml/rat) under anesthesia. Spinal cord was exposed after 
perfusion. Lumbar spinal cord and dorsal root ganglia were collected and 
homogenized with 400 µl and 100 µl of lysis buffer (Promega, WI, USA), 
respectively. After three freeze-thaw cycles, the lysates were centrifuged at 
14,000 g for 5 min at 4°C. Twenty µl of the supernatants was used for the 
luciferase activity assay at room temperature using a luciferase assay kit 
(Promega, WI, USA). Each measurement was carried out for 10 sec in a 
single-well luminometer (Berthold Lumat LB 9507, Germany). The RLU were 
normalized by the total protein concentration of the cell extracts. 
2.2.6 Flow Cytometry, Immunocytochemistry and Immunohistochemistry 
 For flow cytometric analysis of neurotrophin receptor expression in TrkA-
expressing cell lines NIH3T3.E25 and NIH3T3.TRK1 or primary cortical or 
cerebellar neurons, cells were dislodged from 60 mm culture dishes with 1 
mM EDTA in Hank’s buffered saline, fixed by 4% paraformaldehyde in PBS, 




albumin (BSA) in PBS, and stained with rabbit anti-TrkA or anti-TrkB or anti-
TrkC antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 hr. 
After washing with PBS, cells were then stained by sheep anti-rabbit IgG-
FITC (Sigma-Aldrich, St. Louis, MO, USA) for 30 min. Cells were washed and 
re-suspended with PBS. Flow cytometry was processed with Coulter Flow 
Cytometer at the Clinical Research Center, National University of Singapore. 
For immunostaining of primary cortical neurons, cells were grown on 
coverslips and transfected as described above. Cells were briefly washed 
with PBS and fixed with ice-cold methanol at -20°C for 20 min. The air-dried 
samples were washed with PBS and blocked with 1% BSA in PBS, followed 
by incubation with rabbit anti-TrkA or anti-TrkB or anti-TrkC antibodies (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and goat anti-luciferase antibody 
(Promega, WI, USA) for 1 hr. After washing with PBS, cells were incubated 
with donkey anti-rabbit IgG-Cy3 (Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA) and donkey anti-goat IgG-FITC (Research 
Diagnostics, Flanders, NJ, USA) for 30 min. Coverslips were mounted in 
FluoSave Reagent (Calbiochem, Ja Jolla, CA, USA) and examined under a 
Zeiss confocal microscope at the Clinical Research Center, National 
University of Singapore. 
For immunohistochemistry, all rats under anaesthesia were perfused with 
0.1 M PBS followed by 2% paraformaldehyde in 0.1 M PBS. Spinal cords 
were removed and post-fixed in the same fixative for 24 hr. Then the samples 




at 4°C. Frozen horizontal sections of the spinal cord were cut at 30 mm 
thickness and mounted on slides. Sections were washed for 20 min in 0.1 M 
PBS and then incubated overnight with anti-OX42 monoclonal antibody 
(Harlan Sera Lab, Leicestershire, UK; dilution 1:500). After incubation, 
sections were rinsed in PBS for 15 min and reacted with Vectastain ABC Kit 
(Vector Laboratories, Burlingame, CA, USA) against mouse IgG for 1 hr. They 
were then treated with 3,3’-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich, St. Louis, MO, USA) as a peroxidase substrate. The sections were 















3.1 Studies Using Bacterially Produced Polypeptides 
3.1.1 Expression of Recombinant Cationic Polypeptides 
Recombinant DNA method was used to produce a recombinant 
polypeptide comprising a hairpin motif of NGF as a targeting ligand and a 10-
lysine sequence as a DNA binding moiety. The targeting ligand was derived 
from amino acid residues 80-108 of NGF that contains the four residues of 
loop 4 and part of the C and D b strands (designated as NL4). The loop 4-
flanking regions of NGF were included in order to stabilize the native 
conformation of the loop 4 through the formation of hydrogen bonds between 
two b strands. The three-dimensional structure was further stabilized by the 
disulfide bond formed between C80 and C108 of NGF. The gene encoding 
NL4 together with a 10-lysine sequence at its C-terminus or NL4 alone was 
introduced into pET40b(+) expression vector by molecular cloning (Figure 
3.1). These sequences were expressed in E.coli system together with DsbC, 
an E. coli disulfide bond isomerase that should enhance polypeptide stability, 
solubility and folding. The product was designated as DsbC-NL4-10K and the 
control, without the 10-lysine sequence, was designated as DsbC-NL4 
(Figure 3.2A).  Western blotting demonstrated the expression of DsbC-NL4-
10K and DsbC-NL4 in E.coli using a His-tag antibody (Figure 3.2B). 







Figure 3.1 Schematic of expression plasmids. Genes encoding NL4 or 
NL4-10K sequence were generated by PCR and inserted into the expression 








Figure 3.2 Structure and production of recombinant polypeptides. (A) 
NGF loop 4-containing sequence (#80-108) was expressed in E. coli as a 
fusion polypeptide, designated as DsbC-NL4. The other fusion polypeptide 
with the appendage of a DNA-binding sequence of 10-lysine at the C-
terminus to DsbC-NL4 sequence was also produced in E. coli to form a NGF 
receptor-targeted vector, designated as DsbC-NL4-10K. (B) Western 
blotting with antibody against His6 tag confirmed the expression of DsbC-




3.1.2 Activation of TrkA, Erk and Akt by DsbC-NL4-10K 
Activation of TrkA receptor, an NGF receptor, by DsbC-NL4-10K was 
tested in TrkA-positive PC12 cells. NGF is known to induce the 
autophosphorylation of TrkA on Tyr490 (Obermeier et al., 1993) and activate 
the pathway of Ras-MAP kinase, Erk1/Erk2 (p44 and p42 MAP kinases) 
(Payne et al., 1991). Activation of TrkA receptor by NGF is also known to 
trigger Akt signaling cascade, which plays a critical role in cell survival 
(Franke et al., 1997). Similarly, DsbC-NL4-10K induced TrkA phosphorylation 
on Tyr490 and activated Erk1/Erk2 (Figure 3.3). Furthermore, DsbC-NL4-10K 
activated Akt pathway (Figure 3.3). At the same concentration used, DsbC-
NL4 also activated Erk and Akt, although to a lesser extent. The result 
suggests that DsbC-NL4-10K binds to TrkA receptor and the appendage of 
10-lysine to the C-terminal of DsbC-NL4 does not affect the receptor binding 















Figure 3.3 Activation of TrkA, Erk and Akt by DsbC-NL4-10K. PC12 
cells were incubated in RPMI-1640 medium containing 0.5% FBS and 
0.25% horse serum as stated in Materials and Methods and treated for 15 
min with 10 ng/ml NGF, 5 mM DsbC-NL4, 5 mM DsbC-NL4-10K or serum 
free RPMI-1640 without additives. The cell lysates were collected for 
Western blotting using antibodies against Phospho-TrkA, Phospho-p44/p42 
MAPK or Phospho-Akt. 











3.1.3 Promotion of PC12 Cell Survival by DsbC-NL4-10K 
To assay the neuroprotective effect of DsbC-NL4 and DsbC-NL4-10K 
polypeptides, differentiated PC12 cells deprived of serum and NGF were 
used as an evaluation model (Franke et al., 1997;Dago et al., 2002). 
Withdrawal of serum and NGF from medium induces loss of differentiated 
PC12 cell viability; recombinant polypeptides were added to medium to 
prevent cell death. Figure 3.4 showed that addition of DsbC-NL4 prevented 
PC12 cells death with 71-92% of the maximum survival promoted by 10 ng/ml 
NGF. For DsbC-NL4-10K, 12-67% of the maximum survival promoted by 
NGF was observed. This observation also indicates that DsbC-NL4-10K binds 
















Figure 3.4 Promotion of neuronally differentiated PC12 cells survival in 
serum-free medium by DsbC-NL4-10K. Differentiated PC12 cells were 
deprived of serum and NGF for 4 days. DsbC-NL4 or DsbC-NL4-10K was 
added at the time of serum and NGF withdrawal and 10 ng/ml NGF was 
used as a positive control. Cell survival was estimated using a MTT assay. 
Cell survival mediated by the recombinant polypeptides was expressed as 





3.1.4 Binding of DsbC-NL4-10K to Plasmid DNA 
The binding ability of DsbC-NL4-10K to plasmid DNA was monitored by 
DNA retardation assay. While DsbC-NL4-10K complexed with plasmid DNA, 
the positively charged amino groups (N) in 10-lysine tail will neutralize the 
negatively charged phosphate groups (P) of DNA and thus result in the loss 
of electrophoretic mobility of DNA. At proper N/P ratio, the binding oligolysine 
will neutralize all the negative charge of DNA and plasmid will be immobilized 
on gel. Figure 3.5 showed that plasmid DNA gradually lost its mobility with the 
increase of DsbC-NL4-10K concentration. However, plasmid DNA was not 
totally retarded even at a theoretic N/P ratio of 10. This is understandable for 
that the high molecular mass of DsbC-NL4-10K polypeptide on one hand can 
provide shielding effect for protecting DNA, on the other hand can hinder 
more condensed complex formation. Particles formed at N/P ratio of 10 had 
their sizes lied between 200-300 nm while measured by Light Scattering 
Method. This indicated that DsbC-NL4-10K could still condense plasmid DNA 
to certain extent. While DsbC-NL4 and bovine serum albumin (BSA) were 
used as control, no change in mobility of DNA was observed at all testing w/w 





Figure 3.5 DNA retardation by DsbC-NL4-10K. DsbC-NL4-10K, but not 
DsbC-NL4 or bovine serum albumin (BSA), binds to plasmid DNA and 




3.1.5 Enhanced Polycation-mediated Gene Delivery to PC12 by 
DsbC-NL4-10K 
The ability of DsbC-NL4-10K to improve polycation-mediated gene 
transfer was tested in PC12 cells, which express NGF receptors. For this 
purpose, the ternary complexes were prepared. DsbC-NL4-10K was mixed 
with DNA first; PEI600 was then added at a fixed N/P ratio of 20. Figure 3.6 
showed that PEI600 alone was not an efficient vector. With the help of DsbC-
NL4-10K, 6 times higher gene transfer was observed. As controls, the 
addition of either DsbC-NL4, the polypeptide without 10-lysine sequence or 
10K, a synthetic 10-lysine peptide as non-targeted control, didn’t enhance the 
gene delivery. The results suggest that the NL4 domain, but not the 10-lysine 
sequence plays major role in the enhancement of gene transfer to PC12. 
To further verify the contribution of DsbC-NL4-10K, the expression 
patterns of reporter gene after ternary complexes-mediated gene transfer 
were compared in NGF receptor-expressing PC12 and NGF receptor-
negative COS7 cells. As shown in figure 3.7A, DsbC-NL4-10K enhanced 
PEI600-mediated gene delivery in PC12 cells; in COS7 cells, DsbC-NL-10K 
had little contribution to gene delivery. Besides PEI600, the capability of 
DsbC-NL4-10K to enhance gene delivery by protamine, a small arginine-rich 
cationic molecule was also tested. The protamine-containing complexes were 
formed in a similar way as PEI600-containing complexes with a 
protamine/DNA (w/w) ratio of 2. Figure 3.7B showed that DsbC-NL4-10K 




PC12 at low dosage and at higher dosage, the efficiency gradually 
decreased. In COS7, however, DsbC-NL4-10K showed little benefit. The 
observation that the enhancement by DsbC-NL4-10K to both protamine- and 
PEI600-mediated gene transfer was observed in PC12, but not in COS7, 
suggests a NGF-receptor-specific effect of the recombinant cationic 
polypeptide. 
To obtain further evidence of the specific nature of gene delivery mediated 
by DsbC-NL4-10K, PC12 cells grown in 24-well plate were incubated with 
free DsbC-NL4 or DsbC-NL4-10K 30 min before transfection. This pre-
treatment greatly reduced the transfection efficiency of DsbC-NL4-
10K/DNA/PEI600 complexes, as compared to cells pre-treated with BSA 
(Figure 3.8). In contrast, pre-treatment with DsbC-NL4, DsbC-NL4-10K or 
BSA resulted in the similar transgene expression when PEI600/DNA 
complexes are used. This implies that DsbC-NL4-10K-mediated gene delivery 
occurs through receptor binding, because pre-treatment with free DsbC-NL4 













Figure 3.6 Enhanced PEI600-mediated gene transfer by DsbC-NL4-10K 
in PC12. DsbC-NL4-10K/DNA/PEI600 ternary complexes were used to 
transfect PC12 cells. To form the complexes, DsbC-NL4-10K polypeptide 
and pCAGluc plasmid (0.1 mg/well in 96-well plates) were incubated at 
various ratios at room temperature for 30 min in 20 ml OPTI-MEM. After 
that PEI600 was added with a fixed N/P ratio of 20, the complexes were 
incubated for another 30 min. DsbC-NL4 or 10K (a synthetic 10 lysine 
sequence) was also used as non-targeted control for DsbC-NL4-10K. Results 
are expressed in relative light units (RLU)/mg protein ± SE (n=6). *p<0.05, 


































Figure 3.7  Comparison of DsbC-NL4-10K-mediated gene delivery in 
PC12 and COS7 cells. (A) DsbC-NL4-10K enhanced PEI600-mediated 
gene transfer in PC12, but not in COS7. DsbC-NL4-10K/DNA/PEI600 
complexes formed as previously described were used to transfect PC12 and 



















enhanced protamine-mediated gene transfer in PC12, but not in COS7. To 
form DsbC-NL4-10K/DNA/protamine complexes, DsbC-NL4-10K 
polypeptide and pCAGluc plasmid (0.1 mg/well in 96-well plates) were 
incubated at various ratios at room temperature for 30 min in 20 ml Opti-
MEM. After adding protamine (2 mg per mg DNA), the complexes were 












Figure 3.8 Competitive inhibition of DsbC-NL4-10K-mediated gene 
delivery to PC12 cells by DsbC-NL4-10K pre-treatment. PC12 cells were 
pre-treated with DsbC-NL4, DsbC-NL4-10K or BSA before transfection. 
DsbC-NL4-10K/DNA/PEI600 complexes were formed as previous 
described. PC12 cells were exposed to 0.5 mg DNA per well in a 24-well 
plate. Results are expressed in RLU/mg protein ± SE (n=6). *p<0.05, 




3.2 Studies Using Chemically Synthesized Peptides 
3.2.1 Biochemical and Biological Effects of NL4-10K Peptide  
NL4-10K comprises the four residues of NGF loop 4 and the flanking b-
strand sequences (amino acids #80-108, NL4) linked to a C-terminal nucleic 
acid binding domain of ten consecutive lysine residues (10K). The first and 
last amino acid residues of NL4 are cysteine residues, which were oxidized to 
form an intramolecular disulfide bond to stabilize the native structure of loop 
4. The amino acid sequences of NL4 and NL4-10K are listed in Figure 3.9.  
Activation of TrkA receptors by NL4-10K was tested in TrkA-positive PC12 
cells. NGF is known to induce the autophosphorylation of TrkA on Tyr490 
(Obermeier et al., 1993), which in turn elicits signaling cascades that give rise 
to the bioactivity of NGF. Amongst the involved proteins are Erk1 and Erk2, 
part of the Ras-MAP kinase pathway (Payne et al., 1991), and Akt (Franke et 
al., 1997). Similarly, both NL4 and NL4-10K induced TrkA phosphorylation on 
Tyr490 and activated both Erk1/Erk2 and Akt (Figure 3.10A), indicating that 
both NL4 and NL4-10K may bind to TrkA receptors and the appendage of 10 
lysines to the C-terminal of NL4 did not affect the receptor binding and 
bioactivity of NL4-10K. Furthermore, after complexed with plasmid DNA, NL4-
10K maintained its effects to activate TrkA, Erk and Akt (Figure 3.10A), 
suggesting that there were enough accessible NL4 domains on the surface of 
the complexes for TrkA-binding. To further assess the hypothesis that NL4 




AG879, were used to block TrkA protein tyrosine kinase activity (Xie et al., 
2000). As expected, pre-treatment with these inhibitors greatly reduced the 
extent of NL4- and NL4-10K-induced phosphorylation of Erk1 and Erk2 
(Figure 3.10B). These biochemical assays demonstrate that NL4 (with or 
without the 10K domain) may act through TrkA to activate some of the same 
signal transduction pathways that NGF activates. 
One manifestation of survival-promoting bioactivity of NGF is its ability to 
promote survival of PC12 cells grown in serum-free medium, which otherwise 
results in a loss of cell viability (Franke et al., 1997;Dago et al., 2002). 
Differentiated PC12 cells were grown in serum-free medium containing NL4 
or NL4-10K. The cell survival rate, measured by the MTT assay, was 
compared to the survival rate promoted by NGF (10 ng/ml, optimal 
concentration). Over a range of concentrations from 0.125 to 2.5 mM, the 
increasing NL4 concentration resulted in the increasing cell survival rates 
from 68-109% of the optimal NGF-promoted survival rates (Figure 3.11). A 



















Figure 3.10 Effects of NL4-10K on TrkA receptor. (A) Activation of 
TrkA, Erk and Akt by NL4-10K. PC12 cells were incubated in RPMI 1640 
medium containing 0.5% FBS and 0.25% horse serum and treated for 15 min 
with 10 ng/ml NGF, 5 mM NL4, 5 mM NL4-10K, NL4-10K/DNA complexes 
(N/P ratio of 5) or serum free RPMI 1640 without additives. The cell lysates 
were collected for Western blotting using antibodies against Phospho-TrkA, 
Phospho-p44/p42 MAPK or Phospho-Akt. (B) Blocking of NL4-10K-
induced Erk activation by TrkA inhibitors. PC12 cells were pre-incubated 
with or without 100 nM K-252a or 10 mM AG879 for 10 min and then 
treated as described in (A).  The cell lysates were collected for Western 









Figure 3.11 Promotion of neuronally differentiated PC12 cell survival in 
serum-free medium by NL4-10K. Differentiated PC12 cells were deprived 
of serum and NGF for 4 days. NL4 and NL4-10K were added at the time of 
serum and NGF withdrawal and 10 ng/ml NGF was used as a positive 
control. Cell survival was estimated using a MTT assay. Cell survival 
mediated by the peptides was expressed as a percentage of maximal NGF 






3.2.2 NL4-10K Binds to DNA and Mediates In Vitro Gene Transfer 
To examine the possibility of using NL4-10K as a gene delivery vector, we 
first tested whether the peptide could bind to plasmid DNA and neutralize its 
negative charges in a DNA retardation assay. Figure 3.12 showed that the 
mobility of plasmid DNA was reduced with increasing peptide concentrations. 
Between the N/P ratios of 1 and 5, the complex became immobile, indicating 
complete charge neutralization of DNA. In contrast, NL4, which does not 
contain a DNA-binding domain, did not retard DNA migration.  
The physical properties of the complexes were also measured. At N/P 
ratio of 5, the particle size of 10K/DNA polyplexes was 175.0 ± 5.12 nm (n=3), 
while the size for NL4-10K/DNA complexes only slightly increased to 232.7 ± 
4.97 nm (n=3), as expected due to the addition of NL4 domain. Both particles 
were stable over the 160 min measurement time. Polydispersity of the 
particles was typically in the range 0.1 - 0.3, indicating a rather narrow size 
distribution and hence suggesting minimal aggregation in both samples. The 
zeta potentials of both 10K/DNA and NL4-10K/DNA complexes were in the 
same positive range around 20 mV. 
The complexes formed at different peptide/DNA ratios by self-assembly of 
NL4-10K and reporter plasmid pCAGluc were then tested in PC12 cells for 
gene expression (Figure 3.13). Pilot tests confirmed the necessity of using the 
endosome-disrupting agent chloroquine in NL4-10K-mediated gene 




NL4-10K with 1 mg of pCAGluc (N/P ratio of 1) resulted in modest gene 
delivery, but the transfection efficiency increased markedly with an increasing 
amount of NL4-10K. Neither NL4 (targeting domain only) nor 10K (DNA-
binding domain only) nor a mixture of the two exhibited this dose-responsive 
trend. With 1.5 nmol of NL4-10K per mg of DNA (N/P ratio of 5), transfection 
was 110 times more efficient than that achieved with a mixture of NL4 and 

























Figure 3.12 DNA retardation by NL4-10K in agarose gel under 
electrophoresis. 0.1 mg of plasmid DNA was complexed with different 
amount of peptide at the indicated ratios. The complexes were 





              
        nmol/mg:       0       0.03    0.15   0.3   1.5      3 
        N/P ratio:      0       0.1      0.5     1      5        10 
            









Figure 3.13 Efficiency of NL4-10K-mediated gene delivery in vitro. NL4-
10K was used to deliver pCAGluc plasmid DNA to PC12 cells. Short 
peptides, NL4, 10K, and a mixture of NL4 and 10K peptides (NL4 & 10K) 
were used as controls. Cells were transfected with complexes containing 1 
mg of pCAGluc/well in 24-well plates in the presence of 100 mM 
chloroquine. Luciferase expression was assayed 24 hr after the transfection. 
Results are expressed as the mean of RLU/mg protein ± SE (n=4). **P<0.01 









3.2.3 NL4-10K Mediates Gene Delivery through TrkA 
To clarify whether that NL4-10K-mediated gene delivery was targeted to 
TrkA, several types of cells with different expression profiles of NGF receptors 
were used. These cells were first assayed for their neurotrophin receptor 
expression by flow cytometric analysis, using the antibodies from Santa Cruz 
that has been shown to be able to stain Trk receptors in the rat cortex (Miller 
and Pitts, 2000). In NIH3T3 cells, cortex glial cells and primary cerebellar 
granule neurons that are known to be TrkA-negative or TrkA-poor, the 
percentage of TrkA-positive cells was very low or close to zero. In TrkA-
transfected NIH3T3.E25 and NIH3T3.TRK1 cells, approximately 75% and 
67% of the cells were TrkA-expressing respectively (Figure 3.14A), similar to 
the finding from the previous analysis (Bulseco et al., 2001). Interestingly, 
about 87% of PC12 cells and 48% of primary cortical neurons were TrkA-
positive (Figure 3.14A). Figure 3.14B showed TrkB- and TrkC-expressing 
cortical neurons were approximately 24% and 16% respectively, and the 























































Figure 3.14 Flow cytometric analysis of Trk receptors in various cell 
lines and primary cultured cells. (A) Histogram summarizing the 
percentage of cells expressing TrkA receptor (mean ± SE, n=3). Cells were 
incubated with rabbit anti-TrkA, followed by staining with sheep anti-rabbit 
IgG-FITC. Typical flow cytometry results are shown under the histogram. 
(B) Histogram summarizing the percentage of primary cortical neurons and 
cerebellar granule neurons expressing TrkA, TrkB or TrkC (mean ± SE, 
n=3). Cells were incubated with rabbit anti-TrkA or anti-TrkB or anti-TrkC, 
followed by staining with sheep anti-rabbit IgG-FITC. Figures under the 




The specificity of NL4-10K-mediated gene delivery through NGF receptors 
was assessed via a competitive inhibition assay using excess NGF, NL4, or 
NL4-10K to compete with NL4-10K/DNA complexes for access to NGF 
receptors. Treatment by NGF would also produce a rapid clearing of TrkA, up 
to 70%, from the PC12 cell surface (Jullien et al., 2002). As shown in Figure 
3.15A, the presence of NGF, NL4 or NL4-10K during transfection reduced the 
efficiency of gene delivery by 74-90%. The presence of excess 10K peptide, 
however, did not have a significant effect. These findings indicate that the 
NL4-10K-mediated gene delivery into PC12 cells was dependent on those 
sites that can be recognized and bound by NGF.  
Since PC12 cells also express p75NTR receptors that could bind NGF, 
another competitive assay was carried out using p75NTR-blocking antibody 
(Advanced Targeting Systems, San Diego, CA, USA) (Curtis et al., 1995) 
during NL4-10K-mediated transfection to investigate the possible involvement 
of p75NTR. This antibody, as well as its control IgG, did not affect NL4-10K-
medited gene expression significantly (Figure 3.15A), suggesting that the 
gene delivery through p75NTR was less likely. This is further supported by 
gene transfer experiments in two TrkA-expressing, p75NTR-negative NIH3T3 
cell lines, E25 and TRK1 (Cordon-Cardo et al., 1991;Klein et al., 
1991a;Decker, 1995). NL4-10K-mediated reporter gene expression in E25 
and TRK1 was 25-fold and 133-fold higher, respectively, than that in the 




NL4-10K could mediate gene delivery through TrkA without involvement of 
p75NTR. 
To investigate the potential ability of NL4-10K to target gene delivery to 
specific subpopulations of neurons expressing TrkA, but not those expressing 
TrkB or TrkC, primary cortical neurons, cerebellar granule neurons and glial 
cells were used. The expression of TrkA and other Trk receptors in primary 
cultures of cortical neurons was documented in previous studies (Miranda et 
al., 1996;Seabold et al., 1998;Miller and Pitts, 2000;Dubus et al., 2000;Lee et 
al., 2000) and confirmed by flow cytometric analysis (Figure 3.14), which 
further provided the proportion of three Trk receptors in primary cortical 
neurons. In glial cells, the presence of TrkA is still a matter of contention and, 
if present at all, TrkA is expressed in a small percentage of glial cells and at 
low levels (Sofroniew et al., 2001). Primary cerebellar granule neurons are 
known to express significant levels of TrkB and TrkC, but not TrkA 
(Nonomura et al., 1996), which was also shown in the present flow cytometric 
analysis (Figure 3.14B). Complexes formed at the peptide/DNA (nmol/mg) 
ratio of 0.75 (N/P ratio of 2.5) by self-assembly of NL4-10K, or its control 
peptide 10K, and reporter plasmid pCAGluc were used together with 100 mM 
chloroquine in transfection. Figure 3.15C shows that NL4-10K/pCAGluc 
complexes were 22-fold more efficient than the non-targeted control using 
10K in gene transfer to primary cortical neurons. In cerebellar granule 
neurons, however, the difference between the transfection efficiencies of 




both NL4-10K and 10K were inefficient in gene delivery (Figure 3.15C). 
Immunostaining of transfected primary cortical neurons was also performed 
using antibodies against TrkA, TrkB or TrkC together with an antibody against 
luciferase to further examine the TrkA-specificity. The double staining 
disclosed a high degree of co-localization of luciferase with TrkA-positive 




































Figure 3.15 Specificity of NL4-10K-mediated gene delivery. (A) 
Competitive inhibition of NL4-10K-mediated gene delivery into PC12 by 
NGF. PC12 cells were transfected, in the presence of 100 mM chloroquine, 
with NL4-10K/pCAGluc complexes prepared with a peptide/DNA (nmol/mg) 
of 1.5 (N/P ratio of 5), with or without co-incubation with free NGF, NL4, 
10K, NL4-10K or anti-p75NTR antibody. Luciferase activity is expressed as 
mean of RLU/mg protein ± SE (n=4). *P<0.05 and **P<0.01 compared to 
transfection without additives. (B) NL4-10K-mediated gene delivery in TrkA-
expressing NIH3T3 cell lines and parental NIH3T3 cells. Two TrkA-
expressing cell lines, NIH3T3.E25, NIH3T3.TRK1 and parental NIH3T3 cells 
were transfected as described in (A). Luciferase expressions were compared 
(n=4). **P<0.01 compared to transfection in parental cell line NIH3T3. (C) 
NL4-10K mediates gene delivery into primary cortical neurons, primary 
cerebellar granule neurons and glial cells. Primary cortical neurons and glial 
cells from the rat cortex and primary cerebellar granule neurons were 
transfected with complexes containing 1 mg of pCAGluc/well in a 24-well 
plate in the presence of 100 mM chloroquine. After 4 hr, an equal volume of 
normal culture medium was added and incubated for 24 hr before luciferase 



















Figure 3.16 Co-localization of Trk receptors and luciferase 
immunoreactivity in primary cortical neurons after transfection with 
NL4-10K/pCAGluc complexes. Cells were grown on coverslips. Rabbit 
anti-TrkA or anti-TrkB or anti-TrkC together with goat anti-luciferase were 
used for staining after transfection, followed by staining with donkey anti-
goat IgG-FITC and donkey anti-rabbit IgG-Cy3. The mounted coverslips 
were observed and photographed under confocal microscope. Luciferase 
immunoreactivity was shown in green, Trk receptor in red, and double 




3.2.4 NL4-10K-containing Complexes Mediate Gene Delivery to DRG 
In Vivo 
As chloroquine was not suitable for in vivo application, this study 
introduced PEI600, a cationic polymer with endosome-disrupting ability and 
low toxicity, into NL4-10K/DNA complexes and tested gene transfer of the 
ternary complexes in the absence of chloroquine. PEI600 was mixed with 
DNA and NL4-10K was then added to form PEI600/DNA/NL4-10K ternary 
complexes. Figure 3.17A showed that the gene transfer efficiency by PEI600 
alone in PC12 cells was low at all tested N/P ratios and the addition of 10K 
peptide into the PEI600/DNA complexes did not improve the efficiency. 
However, while NL4-10K was introduced into the PEI600/DNA complexes 
formed at N/P ratios of 5 and 10, gene expression increased with a dose-
response manner, with the highest reading at ~2 x105. When the N/P ratio of 
PEI600/DNA reached 20, the addition of NL4-10K peptide failed to offer 
further improvement. 
A large portion of dorsal root ganglion (DRG) cells expressed TrkA 
receptors (Ruit et al., 1990) and intrathecally applied nerotrophins may 
penetrate into the DRG (Jones et al., 1999). To test the NL4-10K-mediated 
gene delivery in vivo, rats were given PEI600/pCAGluc/ NL4-10K complexes 
via intralumbar injection. In the spinal cord near the lumbar injection site, 
transfection mediated by NL4-10K was lower relative to that offered by the 
10K control. In contrast, luciferase gene expression in the DRG resulting from 




PEI600/pCAGluc/10K (Figure 3.17B), suggesting a targeting effect of NL4-



































Figure 3.17 Gene delivery mediated by NL4-10K-containing complexes. 
(A) NL4-10K-mediated gene delivery without chloroquine in PC12 cells. To 
prepare PEI600/DNA/NL4-10K, pCAGluc was first complexed with PEI600 




2.5 or 5. PC12 cells were transfected with complexes containing 1 mg of 
pCAGluc/well in a 24-well plate. After 4 hr, an equal volume of normal 
culture medium was added and the cells were incubated for 24 hr before 
luciferase expression assay. *P<0.05 or **P<0.01 compared to the controls 
without peptides (n=6). (B) NL4-10K-mediated in vivo gene delivery into 
dorsal root ganglia (DRG). PEI600/DNA/NL4-10K complexes were formed 
as described above, at a peptide/DNA (nmol/mg) ratio of 1.5 (N/P ratio of 5). 
Complexes were administered intrathecally to rats under anesthesia. Lumbar 
spinal cord (SC) and DRG were collected 3 days after injection. Results are 





3.2.5 Biocompatibility of PEI600/DNA/NL4-10K Ternary Complexes 
Because of the introduction of cationic polymer PEI600 that disrupts 
endosomal membranes into the complexes and also because of the high 
positively charged 10K domain, in vitro cytotoxicity of PEI600/DNA/NL4-10K 
complexes was tested by MTT assay in primary cortical neurons. PEI600 was 
mixed with DNA at N/P ratio of 10, NL4-10K was then added to form 
PEI600/DNA/NL4-10K complexes at the indicated total N/P ratio. Results 
showed the lack of toxicity of the complexes at the tested N/P ratios (Figure 
3.18A). As a positive control, PEI25kDa/DNA complexes showed apparent 
toxicity to primary cortical neurons (Figure 3.18A). Tissue compatibility of 
PEI600/DNA/NL4-10K complexes was assayed by using microglial activation 
marker OX42 to detect inflammatory responses that could be triggered 
directly by a gene delivery vector or indirectly by cell/tissue injury (Popovich et 
al., 1997). The complexes showed no toxic effects in the spinal cord region 
close to the injection site, while the positive control PEI25kDa/DNA 
complexes triggered a clear inflammatory response, as assessed by 

































Figure 3.18 Biocompatibility of NL4-10K-containing complexes. (A) 
Cytotoxicity of NL4-10K-containing complexes in primary cortical neurons. 
PEI600 was mixed with DNA at N/P ratio of 10, and NL4-10K was then 
added to form PEI600/DNA/NL4-10K complexes at the indicated total N/P 
ratio. PEI25kDa/DNA complexes formed by mixing PEI25kDa with plasmid 
DNA at the indicated ratios were used as a positive control. Complexes were 
added at 0.1 µg DNA/well of 96-well plate. Cell survival was estimated 
using a MTT assay and expressed as a percentage of control, the untreated 
sister cultures. (B) Immunoreactivity of OX42 in the spinal cord after 
intrathecal injection of NL4-10K-containing complexes. PEI600 was mixed 
with DNA at N/P ratio of 10, and NL4-10K was then added at N/P ratio of 5 
to form PEI600/DNA/NL4-10K complexes. PEI25kDa/DNA complexes 
formed with N/P ratio of 15 was used as a positive control. Three µg 
DNA/60 µl of complexes were injected intrathecally. Samples were 
collected 3 days after injection and the tissue sections were stained with anti-















Cell-specificity is one of the main objects for the development of gene 
delivery system. This property is highly desired for the effective application of 
gene therapy, especially in the nervous system. In this study, two NGF loop 
4-containing chimeric polypeptides produced by either biological or chemical 
methods were used to prove the concept of targeted gene transfer to cells 
expressing NGF receptor TrkA. 
4.1 Studies Using Bacterially Produced Polypeptides 
In the first part of this study, to prove the concept of using NGF mimetic as 
targeting ligand for gene delivery, a recombinant polypeptide comprising a 
NGF loop 4-containing hairpin motif and a decalysine sequence was 
expressed in E. coli together with a DsbC fusion portion. This polypeptide 
DsbC-NL4-10K was able to direct gene transfer to NGF-receptor expressing 
cells. The binding of the polypeptide to NGF receptor was demonstrated by its 
ability to activate TrkA receptor and its downstream signaling pathways and to 
promote the survival of differentiated PC12. Specificity of the polypeptide-
mediated gene transfer was evident by its efficiency in NGF receptor 
expressing cells, but not in receptor-negative cells and the inhibition of 
transgene expression by pre-treatment of free polypeptides.  
4.1.1 The design and production of polypeptides 
The design of the polypeptide was based on the current knowledge of 
NGF structure and its interaction with NGF receptors. Various approaches, 




crystal structure analysis, have been used to study structural determinants of 
NGF effects. These studies have confirmed the amino acid residues that are 
important for receptor binding are localized in N-terminal region (#1-8), 
variable region II (#40-49) and variable region V (#96-97) (The variable region 
V corresponds to loop 4 in (Wiesmann et al., 1999;Wiesmann and de Vos, 
2001)) (Ibanez, 1995). These studies raise the possibility of designing small 
peptide units that biochemically and biologically mimic the large and complex 
native NGF. It has been reported that small peptide mimetics of NGF activate 
TrkA-related signal transduction and promote NGF-like neurotrophic effects 
(LeSauteur et al., 1995;Beglova et al., 1998;Xie et al., 2000;Beglova et al., 
2000;Maliartchouk et al., 2000). These peptide mimetics need to be cyclic in 
order to be biologically active; they must not only be sequence analogs but 
also structural analogs of NGF loops.  
In the first part of the study, a 29-amino acid long hairpin motif from NGF 
was employed as targeting ligand. This loop 4-containing motif includes 
sequence from C80 to C108 [The numbering of amino acids refers to 
(Wiesmann et al., 1999;Wiesmann and de Vos, 2001)]. In addition to the four 
amino acid residues of loop 4, this structure includes as well parts of the C 
and D β strands of NGF that may stabilize the natural conformation of the 
loop through the formation of hydrogen bonds between two β strands. The 
three-dimensional structure is further stabilized by the disulfide bond formed 
between C80 and C108 after oxidation. Different from a full-length native NGF 




NGF used in the present study contains only two residues of cysteine. Thus, 
mismatched disulfide bond linkage, a problem often seen in the production of 
recombinant native polypeptide, is avoided and unfolding/refolding of 
recombinant polypeptide to form correct disulfide bonds would be 
unnecessary, making this polypeptide preparation relatively easier. By using a 
hairpin motif instead of a simple loop artificially cyclized at two ends, it is 
expected that the loop conformation and the flexibility required for induced-fit 
ligand recognition by NGF receptors will be better conserved. Previous 
studies have suggested that a short positively charged lysine tail was enough 
for DNA binding (Gottschalk et al., 1996). Here, a 10-lysine sequence was 
introduced at the C-terminus of the hairpin motif to form the chimeric 
polypeptide-based nonviral vector. The sequence was expressed together 
with a DsbC protein, an E. coli disulfide bond isomerase to enhance the 
protein stability, solubility and folding. While used as a DNA vector, this DsbC 
fusion protein on one hand could potentially protect DNA from enzyme attack 
owing to the shielding effect provided by the bulky domain; on the other hand, 
it might also hinder the binding and condensation of DNA. A short synthetic 
peptide might avoid the problem caused by a bulky structure, however, a 
recombinant polypeptide approach such as the one used in this study offers 
opportunities to produce a single polypeptide chain based-vectors by 
incorporating multiple functional domains to overcome the barriers at different 
stages of gene transfer, from cellular internalization, endosomal escape, 




4.1.2 The polypeptide-containing complexes 
To study the targeting ability of the recombinant polypeptide for in vitro 
gene transfer, protamine, a small arginine-rich peptide, as well as low MW 
PEI600 were used to form DsbC-NL4-10K-containing complexes. Similar 
systems have been used in studies using protamine (Medina-Kauwe et al., 
2001a;Medina-Kauwe et al., 2001b). Here PEI600 was introduced due to its 
low toxicity and moderate endosome-disrupting and DNA-binding ability (Ahn 
et al., 2002). With these complexes, other endosome-disrupting agent like 
chloroquine, which might be unsuitable for in vivo study was obviated. As 
observed in this study with these ternary complex systems, a low 
polypeptide/DNA ratio was required to enhance polycation-mediated gene 
delivery in PC12; at higher ratio, excess and/or unbound polypeptides might 
give rise to competitive inhibition by saturating the binding sites on the cell 
surface. Therefore, the intrinsic competition between the polypeptide and the 
polycation for DNA binding in these ternary systems requires the optimization 
of polypeptide/polycation/DNA ratio. With high polycation/DNA ratio, the 
targeting polypeptide could be expelled and vise versa. One possible solution 
to this issue is to include a functional domain with endosome-escaping 
mechanism in the same recombinant polypeptide molecule. This endosome-
disrupting sequence could be N-terminal amphiphilic peptide of influenza 





In brief, this preliminary research demonstrated the concept of using a 
loop 4-containing hairpin motif from NGF for targeted gene delivery with 
bacterially produced recombinant polypeptide. This motif has shown its 
biochemical and biological functions by activating the TrkA-related signal 
transduction pathways and preventing the cell death of differentiated PC12. 
While incorporating a DNA-binding sequence of 10 lysines, the motif may also 
direct the gene delivery to NGF receptor-expressing cell. Since this 
polypeptide was expressed as a DsbC fusion protein, the bulky fusion domain 
may affect both the binding of NGF loop 4-containing hairpin motif to its 
receptor and the binding of the 10-lysine sequence to the DNA. To overcome 
these issues, a chemically synthesized peptide simply composed of the 
targeting moiety derived from NGF loop 4 and the DNA-binding moiety of 10 
lysine residues was employed for more systemic study.  
4.2 Studies Using Chemically Synthesized Peptides 
The second part of this study further showed that a chemically 
synthesized peptide containing the hairpin motif of NGF loop 4 linked to a 
nucleic acid binding domain was capable of directing gene delivery to TrkA 
receptors. Several lines of evidence support this conclusion: (1) The peptide, 
even after binding to DNA, possessed NGF-like bioactivities in TrkA-positive 
PC12 cells; (2) The peptide dose-dependently directed gene delivery to PC12 
cells; (3) Gene transfer to PC12 cells was inhibited by co-incubation of excess 
amounts of NGF or free NGF loop 4 containing peptides, but not by a p75NTR 




expression in p75NTR-negative NIH3T3 cells heterologously transfected with 
TrkA cDNA; (5) The peptide did not mediated gene expression in primary 
cerebellar granule neurons, as well as cortex glial cells, that are TrkB- and/or 
TrkC-positive, but TrkA-negative; (6) The peptide would have to contain both 
TrkA-targeting and DNA-binding domains in order to be functional in gene 
delivery; (7) The peptide-mediated gene expression required the use of 
endosome-disrupting agents, being consistent with the understanding that 
NGF-TrkA binding triggers endocytosis. Thus, this may be the first report 
using NGF loop fragments and TrkA receptors in targeted gene delivery to 
neurons. 
4.2.1 The design of targeting ligand 
The design of the peptide vector was inspired by the successful 
development of small NGF mimetics (LeSauteur et al., 1995;Longo et al., 
1997;Beglova et al., 1998;Xie et al., 2000;Beglova et al., 2000;Maliartchouk et 
al., 2000) and based on the molecular basis of NGF-receptor interaction. NGF 
loop 4 is a hydrophilic hairpin loop exposed on NGF surface, serving as one 
of the two primary NGF loop domains interacting with TrkA receptors 
(Drinkwater et al., 1993;Kullander et al., 1997). Using the sequence of this 
region, small molecule ligands of TrkA with less than 10 residues of amino 
acids had been successfully generated (LeSauteur et al., 1995;Beglova et al., 
1998;Xie et al., 2000;Beglova et al., 2000). These small NGF mimetics have 
cyclized structures, being both sequence and structure analogs to the NGF 




amino acid #80-108 of NGF was synthesized and cyclized with a disulfide 
bond formed between C80 and C108 for TrkA targeting. In addition to loop 4 
sequence, the peptide includes as well parts of the C and D β-strands of 
NGF, in an attempt to use natural β-strand structures to stabilize the native 
conformation of the loop 4. Such a hairpin motif structure may also provide 
flexibility required for induced-fit ligand recognition of receptor. To construct a 
DNA vector, a 10-lysine sequence was introduced to the C-terminus of NL4 to 
form NL4-10K. While the 10K part binds DNA, β-strands in the chimeric 
peptide may function as spacers between NGF loop 4 and the 10K/DNA 
complex, allowing independent action of the targeting domain and the DNA-
binding domain. Furthermore, using a fragment of NGF polypeptide 
containing a hairpin motif, instead of the full-length polypeptide chain, 
susceptibility to proteolytic degradation and immunogenicity of the 
polypeptide during in vivo application would be reduced. 
4.2.2 The binding of ligand to TrkA 
Consistent with the notion that the NGF loop 4 is one of the key sites 
interacting with TrkA (LeSauteur et al., 1995;Beglova et al., 1998;Xie et al., 
2000;Beglova et al., 2000), the peptides NL4 and NL4-10K developed in the 
study activated TrkA and its downstream signaling components, Erk and Akt. 
The inhibition of NL4-mediated Erk activation by TrkA kinase inhibitors K252a 
and AG879 indicated that the action was most likely through TrkA receptor 
itself. NL4 and NL4-10K peptides also promoted the survival of differentiated 




peptides bind to and act via TrkA. Moreover, NL4-10K showed similar activity 
as NL4 peptide even when it was complexed with DNA, a property critical to 
its use as a gene delivery vector. It is noticeable that without DsbC fusion 
portion that may produce spatial hindrance and/or affect loop 4 conformation, 
the chemically synthesized peptides show higher efficacy in TrkA-binding as 
evidenced by their biochemical and biological functions, comparing to their 
recombinant counterparts.  
4.2.3 The selectivity in peptide-mediated gene delivery  
A challenging issue of this study is to establish the TrkA selectivity of NL4-
10K peptide in gene delivery process. Preliminary data collected support the 
notion that the uptake of NL4-10K/DNA complexes is mediated by TrkA, but 
not p75NTR, TrkB or TrkC. Several previous studies in PC12 cells have 
confirmed that p75NTR does not take part in the actual physical internalization 
of NGF (Eveleth and Bradshaw, 1992;Kahle et al., 1994;Gargano et al., 
1997;Jullien et al., 2002). It has been confirmed as well in Chinese hamster 
ovary fibroblasts over-expressing TrkA that TrkA, in the absence of p75NTR, is 
fully capable of mediating NGF endocytosis (Zapf-Colby and Olefsky, 1998). 
Consistently, in the present experiments a p75NTR receptor blocking antibody 
failed to inhibit NL4-10K-mediated gene transfer in PC12 cells that express 
both low affinity p75NTR and high affinity TrkA receptors and the gene transfer 
took place efficiently in two stably transfected NIH3T3 cell lines expressing 
only TrkA. Structurally, several residues in NGF loop 4 are also of importance 




(Ibanez, 1995). These residues however need to function together with NGF 
loop 1 (residues 29-35) for binding to p75NTR (Longo et al., 1990;LeSauteur et 
al., 1995;Shamovsky et al., 1999). As for TrkB and TrkC, the low efficiency of 
NL4-10K peptide in the transfection experiments using primary glial cells and 
cerebellar granule neurons, which mainly express TrkB and/or TrkC, but not 
TrkA (Condorelli et al., 1995;Nonomura et al., 1996), does not support the 
possibility that these two receptors had participated in NL4-10K-mediated 
gene transfer. 
Ligand-induced dimerization of cell surface receptors has been regarded 
as a general mechanism for the initiation of downstream processes, including 
endocytosis of ligand/receptor complexes (Sofroniew et al., 2001), although 
extensive evidence has emerged to challenge this dogma (Mischel et al., 
2002;Pattarawarapan and Burgess, 2003). Dimeric native NGF may induce 
TrkA dimerization, initiating NGF signal transduction. Monomeric and 
monovalent ligands of TrkA have been shown to function as partial agonists, 
acting allosterically through the receptor rather by inducing receptor 
dimerization (Maliartchouk et al., 2000). In general, peptides used in this 
study are a monomeric ligand and their bioactivities may be the result of 
conformational changes of TrkA receptors. With the introduction of 10-lysine 
sequence into the peptide, these positively charged basic amino acid 
residues could bind to the weakly negatively charged cell surface, creating 
locally concentrated peptides that offer the opportunity for receptor 




would be available on the surface of each complex. Theoretically, in NL4-
10K/pCAGluc complexes formed at N/P ratio of 1, there will be ~1400 NL4-
10K molecules available for binding to each plasmid DNA molecule; at higher 
N/P ratio, the number becomes even larger. It is possible that neighboring 
pairs of tethered peptides act as dimers to facilitate receptor dimerization and 
subsequent receptor-mediated endocytosis of the complexes. Further 
structural analysis of receptor-ligand complexes is required to decipher the 
mechanisms involved.  
4.2.4 The peptide-containing complexes 
A typical vector for receptor-mediated gene transfer is composed of a 
cationic polymer of synthetic origin chemically conjugated with a targeting 
ligand. This approach requires chemical reactions that could be harsh enough 
to inactivate sensitive targeting ligands. In the case of using proteins that are 
difficult to be purified or synthesized as targeting ligands, the relative large 
amounts of material required for chemical conjugation could be prohibitively 
expensive, limiting the development and testing of such gene delivery 
systems and the scale-up necessary for gene therapy. The peptide developed 
in this study contains a lysine-based DNA-binding domain, necessitating the 
use of an endosomolytic agent, such as chloroquine. For in vivo gene 
delivery, the peptide could be used together with those cationic polymers that 
may promote endosomal escape, e.g. PEI, to form DNA complexes through 
charge interaction between the macromolecules. By preparing a gene 




use of harsh and reagent-wasteful chemical reactions and expect to see 
better-conserved biological activities of peptide-based targeting ligands. The 
including of cationic polymers, like PEI, in such a ternary system also reduces 
the amount of peptide needed to condense DNA. 
In this study, low MW, branched PEI600 was used to form NL4-10K-
containing complex. PEI600 has repeated basic units with a backbone of two 
carbons followed by a nitrogen atom and contains primary, secondary and 
tertiary amino groups, each of which has the potential to be protonated, 
therefore disrupting endosome membrane (Ahn et al., 2002). This polymer 
was picked up in this study mainly due to its low immune stimulating effect 
and low cytotoxicity. Although it binds to and condenses DNA, the polymer 
itself mediates very low level of gene transfection at low polymer/DNA ratios, 
thus acting as one component of the ternary complex without pronounced 
effects on the specificity of gene transfer. With the increase of PEI600 in 
ternary complexes, however, the gene delivery may become nonspecific, 
probably due to the excess positive charge on the particle surface and the 
domination of electrostatic interaction. 
4.2.5 The use of oligolysine as DNA carrier  
In this research, to prove the specificity of this newly developed targeting 
ligand in gene delivery is the primary objective. Therefore, a simple design 
consisting of a targeting ligand and a simple DNA-binding sequence of 10 
lysines was chosen. This bi-functional peptide was chemically synthesized, 




random conjugation and polydispersity of polymer. The use of oligolysine may 
also avoid the possible nonspecific electrostatic interaction due to the high-
density positive charge of cationic polymers, which could mask the targeting 
effect via ligand-receptor interaction. However, for efficient intracellular 
trafficking, endosomolytic agents like chloroquine are still required to increase 
the efficiency of this peptide. To improve this targeted gene delivery system, 
the incorporation of other DNA carriers could be one possible direction in the 
future. Gene transfer agents like PEI that have intrinsic endosomolytic 
property may also eliminate the use of chloroquine and make the system 
more suitable for in vivo application. 
4.2.6 The possible intrinsic gene delivery at high +/- charge ratio  
An important concern for the research of targeted gene delivery systems 
is the possible intrinsic gene delivery for cationic DNA carrier used at high +/- 
charge ratio. To prove the targeting effect of a novel ligand in a gene delivery 
system, it will be ideal to conjugate the ligand to a DNA carrier that would not 
produce any nonspecific attachment to the target cell surface. However, the 
current existing DNA carriers, most of which depend on the electrostatic 
action of cationic polymer and anionic DNA, have potential intrinsic binding 
ability to some cell surface molecules like glycosaminoglycans, especially 
while the complexes are produced at high +/- charge ratio (Mislick and 
Baldeschwieler, 1996). To minimize the intrinsic effects of the DNA carrier, 
hydrophilic polymers like polyethylene glycol (PEG) have been employed to 




However, this strategy may also impair the targeting ability of the conjugated 
ligand (Kunath et al., 2003). At present, to differentiate between the intrinsic 
targeting effect provided by the DNA carrier itself and the extrinsic targeting 
effect provided by the targeting ligand remain a serious challenge in this field.   
In the previous research of targeted gene delivery, oligolysine (such as a 
sequence of 16 lysine residues [K]16) has been used as DNA-binding domain 
together with integrin-targeting domain (a RGD-containing sequence with 11 
amino acids in length) in the synthetic peptides known as RGD[K]16 and 
[K]16RGD (Hart et al., 1995;Harbottle et al., 1998). In these studies, the 
optimized +/- charge ratio for in vitro transfection was ~4.28. At this high +/- 
charge ratio, the control peptide [K]16 produced no significant transgene 
expression. Combined with the evidence from competitive inhibition assay, 
the authors claimed the specificity of gene delivery by their integrin-targeting 
peptides. In one related research (Hart et al., 1997), the optimized +/- charge 
ratio was even as high as 6:1.  
The role of electrostatic binding in complexes with high +/- charge ratio did 
raise the concern. In one study (Collins et al., 2000) using a synthetic 31 
amino acid DNA vector (polylysine-molossin) comprising a 15-amino acid 
integrin-targeting sequence and [K]16, the authors have shown that at +/- 
charge ratio of 4/1, although the [K]16/DNA and polylysine-molossin/DNA 
complexes both may bind to target cell surface, however, only polylysine-
molossin/DNA complexes resulted in efficient transgene expression, whereas 




vector systems using oligolysine as DNA binding domain, it is possible that 
while used at high +/- charge ratio, the attachment of vector/DNA complexes 
to the cell surface may involve both ligand-receptor interaction and 
electrostatic interaction. The nonspecific electrostatic interaction may not be 
essential, especially while the affinity of ligand to receptor and the density of 
the targeted cell surface receptor are high. On the other hand, the inefficient 
transgene expression mediated by [K]16/DNA alone suggests that cell surface 
attachment is not enough for gene delivery, while the internalization of 
complexes via binding to the targeted receptor may be important for trangene 
expression. With this receptor-dependent internalization process, the targeted 
vectors may also confer transfection specificity. 
In this study, a chemically synthesized 39-amino acid peptide (NL4-10K) 
was used for targeted gene transfer. There are some potential advantages in 
this design for the purpose of reducing possible of electrostatic effect in 
peptide/DNA complexes. Previous studies have shown that 8-10 lysines is 
adequate for DNA binding (Gottschalk et al., 1996;Medina-Kauwe et al., 
2001a;Medina-Kauwe et al., 2001b). A DNA-binding domain of 10 lysine 
sequence (10K) instead of [K]16 was used, hoping that with less lysines per 
molecule, the nonspecific electrostatic binding to the cell surface would 
reduce. A 29-amino acid sequence (NL4) was used for targeting. With a 
larger targeting domain and a smaller DNA binding sequence in the same 




provide better spatial hindrance effect to shield the positive charge of lysines, 
thus, reduce the electrostatic binding of the complexes.  
In this gene delivery study, optimized complexes of NL4-10K/DNA have 
been formed at +/- charge ratio of 5/1, which is similar to that used in the 
studies using [K]16 considering the less positive charge density in NL4-10K. At 
this ratio, the 10 lysine sequence alone gave no transgene expression, 
whereas NL4-10K was two orders of magnitude more efficient, which at least 
suggests the specificity of NL4-10K-mediated tranfection. In the co-incubation 
study using same molar concentration of free NL4, NL4-10K and 10K (the 
control sequence of 10 lysines), the presence of 10K, which was supposed to 
compete with NL4-10K/DNA complexes for the negatively-charged binding 
sites on the cell surface, didn’t affect the NL4-10K/DNA-mediated transgene 
expression; however, the presence of NL4, which was supposed to compete 
with the complexes for ligand-binding sites or NL4-10K, which was supposed 
to compete with the complexes for both ligand-binding sites and the 
negatively-charged biniding sites, significantly reduce the transgene 
expression. These results suggest that in the case of NL4-10K/DNA 
complexes, the charge interaction may be less important for the attachment of 
NL4-10K/DNA complexes to the cell surface, while the ligand-receptor 
interaction may be more important.  
4.2.7 The competitive inhibition assay 
Competitive inhibition with free ligands is one of frequently used methods 




in the targeted gene delivery study using RGD[K]16 (Hart et al., 1995), in the 
presence of excess free RGD peptide, transgene expression was reduced by 
70%. In another study using epidermal growth factor (EGF) as targeting 
ligand and poly-L-lysine as DNA-binding agent (Frederiksen et al., 2000), the 
presence of excess free EGF only reduced the transfection by ~34-64%. In 
the study that coupled the transferrin to PEI (Kircheis et al., 1997), the excess 
free transferrin reduced the transfection by ~80-86%. From these 
observations, it is likely that depending on the targeting ligands and the DNA-
binding agents and also the targeted cells used, a targeted gene delivery 
system could have various extent of background transgene expression even 
in the presence of excess free ligands.  
There are some possible explanations for the background transgene 
expression in the competitive inhibition assay. Theoretically, at high +/- 
charge ratio, there would be thousands of targeted vector bind to each 
plasmid DNA. This multivalent structure likely have a greater avidity for 
binding through ligand-receptor interaction than the free ligands, which make 
this kind of competitive inhibition assay a little bit different from the traditional 
one. At this high +/- charge ratio, portion of the complexes could also bind to 
the cell surface via electrostatic interaction, and then enter the cell via the 
subsequent receptor-mediated internalization. However, there is still no 
substantial evidence to support this theory. According to inhibition assay in 
this study, free NL4 peptide and NGF reduced the transfection by 74% and 




by 90%. Therefore, this only leaves 10-24% that are not inhibited by free 
ligands co-incubation, which is an acceptable result according to other similar 
research.  
4.2.8 The possibility of receptor-mediated gene delivery using a 
targeted oligolysine-based system at high +/- charge ratio  
To develop a targeted gene delivery system, the introduction of novel 
ligands is one important aspect of the research. To fulfill ligand-directed 
distribution of therapeutic gene to a target site, a DNA carrier system should 
be free from inherent properties that would bias bio-distribution. 
Unfortunately, the currently used cationic DNA carriers may produce non-
specific interaction that would affect the contribution of the targeting ligands. 
Therefore, to study the targeting effect of a novel ligand, a DNA carrier 
system that has less intrinsic properties should be chosen. From this 
viewpoint, oligolysine is a better choice than other polymers like PEI that also 
have endosomolytic property.  
To avoid the polydispersity of polylysine, a short synthetic lysine sequence 
(10K) was used in this study simply for its function of DNA binding or 
condensing. This 10K sequence itself was poor in gene delivery to TrkA-
expressing cells, while only the 10K sequence together with targeting ligand 
(NL4-10K) was efficient. Since both NL4-10K/DNA and 10K/DNA complexes 
have showed similarity in particle size and zeta potential, thus the difference 
in their gene delivery ability was unlikely to be explained by the difference in 




free 10K did not reduce the NL4-10K-mediated gene delivery, while masking 
the TrkA receptor by free NL4-10K did, indicating the targeting effect of the 
NL4 domain at this high +/- charge ratio. Therefore, in this NL4-10K-mediated 
gene delivery, although there could be small portion of nonspecific interaction, 
receptor-specificity gene delivery has been predominant.  
4.2.9 The application 
High-level and cell-specific gene expression are required to effectively 
apply gene therapy approaches to treat many neurological disorders, 
including stroke, ischemia, epilepsy, head and spinal cord trauma, 
Parkinson's diseases, Huntington's disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis, and neurogenetic disorders. The chimeric 
peptide reported here could potentially be useful in gene therapy of the 
disorders, in which neurons expressing TrkA are affected. In Alzheimer’s 
disease, the neurons with most prominent pathological changes are basal 
forebrain cholinergic neurons that express TrkA (Winkler et al., 1998). A gene 
delivery system that targets TrkA may help to transfer therapeutic genes into 
the neurons to augment cholinergic functions. Outside the nervous system, 
NGF and TrkA expression are detected in B lymphocytes, T lymphocytes, 
mast cells, monocytes and macrophages, suggesting a role for NGF in 
immune and inflammatory functions (Sofroniew et al., 2001). In addition, 
human tumor tissues up-regulate neurotrophin receptors and are responsive 
to NGF (Saragovi and Gehring, 2000). The peptide reported in this study is 




tissues. As the peptide alone activates TrkA receptor-related signal 
transduction and exerts NGF-like biological activities, it can also be used 
directly as therapeutic agents in the treatment of the aforementioned 
disorders.  
 
In summary, the present study has demonstrated that an NGF loop 4-
containing hairpin motif, both chemically synthesized and bacterially produced 
recombinant one, can function as a novel ligand for targeted gene delivery. 
The motif can bind to TrkA, mediate in vitro gene transfer via TrkA efficiently, 
and has shown potential targeting ability for in vivo gene delivery to neurons 
without toxicity. The present study provides, for the first time, an example for 
targeted gene delivery to a subtype of neurons and presents a platform to 
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APPENDIX A: AMINO ACID SEQUENCES 
1. Name: human NGF 
Sequence: 
SSSHPIFHRG EFSVCDSVSV WVGDKTTATD IKGKEVMVLG EVNINNSVFK 50 
QYFFETKCRD PNPVDSGCRG IDSKHWNSYC TTTHTFVKAL TMDGKQAAWR 100 
FIRIDTACVC VLSRKAVRR 
 
2. Name: DsbC-NL4 
Sequence: 
MKKGFMLFTL LAAFSGFAQA DDAAIQQTLA KMGIKSSDIQ PAPVAGMKTV 50 
LTNSGVLYIT DDGKHIIQGP MYDVSGTAPV NVTNKMLLKQ LNALEKEMIV 100 
YKAPQEKHVI TVFTDITCGY CHKLHEQMAD YNALGITVRY LAFPRQGLDS 150 
DAEKEMKAIW CAKDKNKAFD DVMAGKSVAP ASCDVDIADH YALGVQLGVS 200 
GTPAVVLSNG TLVPGYQPPK EMKEFLDEHQ KMTSGKGSTS GSGHHHHHHS 250 
AGLVPRGSCT TTHTFVKALT MDGKQAAWRF IRIDTAC 
Features: 
- aa 1-236: DsbC 
- aa 244-249: His6 tag 
- aa 259-287: NL4 
 
3. Name: DsbC-NL4-10K 
Sequence: 
MKKGFMLFTL LAAFSGFAQA DDAAIQQTLA KMGIKSSDIQ PAPVAGMKTV 50 
LTNSGVLYIT DDGKHIIQGP MYDVSGTAPV NVTNKMLLKQ LNALEKEMIV 100 
YKAPQEKHVI TVFTDITCGY CHKLHEQMAD YNALGITVRY LAFPRQGLDS 150 
DAEKEMKAIW CAKDKNKAFD DVMAGKSVAP ASCDVDIADH YALGVQLGVS 200 
GTPAVVLSNG TLVPGYQPPK EMKEFLDEHQ KMTSGKGSTS GSGHHHHHHS 250 
AGLVPRGSCT TTHTFVKALT MDGKQAAWRF IRIDTACKKK KKKKKKK 
Features: 
- aa 1-236: DsbC 
- aa 244-249: His6 tag 
- aa 259-297: NL4-10K 
 
4. Name: NL4 
Sequence: 
CTTTHTFVKA LTMDGKQAAW RFIRIDTAC 
Features: 
- aa 1-29 correspond to aa 80-108 of nerve growth factor 
(NGF) and include loop 4, a known receptor binding region 
- C1 and C29 form a disulfide bridge 
 
5. Name: NL4-10K 
Sequence: 
CTTTHTFVKA LTMDGKQAAW RFIRIDTACK KKKKKKKKK 
Features: 
- aa 1-29 correspond to aa 80-108 of nerve growth factor 
(NGF) and include loop 4, a known receptor binding region 
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- C1 and C29 form a disulfide bridge 
- aa 30-39 form a nucleic acid binding domain 
 




APPENDIX B: NUCLEIC ACID SEQUENCES 
1. NA SEQ 1 




2. NA SEQ 2 
Description: Reverse primer for NL4 
Sequence: 
5’-GCAAGCTTTC AACAGGCCGT ATCTATCCG-3’ 
 
3. NA SEQ 3 
Description: Reverse primer for NL4-10K 
Sequence: 
5’-GCAAGCTTTC ATTTTTTTTT TTTTTTTTTT TTTTTTTTTT TACAGGCCGT 
ATCTATCCG-3’ 
 
4. NA SEQ 4 
Description: Coding sequence for DsbC-NL4 
Sequence: 
atgaagaaag gttttatgtt gtttactttg ttagcggcgt tttcaggctt  50 
tgctcaggct gatgacgcgg caattcaaca aacgttagcc aaaatgggca 100 
tcaaaagcag cgatattcag cccgcgcctg tagctggcat gaagacagtt 150 
ctgactaaca gcggcgtgtt gtacatcacc gatgatggta aacatatcat 200 
tcaggggcca atgtatgacg ttagtggcac ggctccggtc aatgtcacca 250 
ataagatgct gttaaagcag ttgaatgcgc ttgaaaaaga gatgatcgtt 300 
tataaagcgc cgcaggaaaa acacgtcatc accgtgttta ctgatattac 350 
ctgtggttac tgccacaaac tgcatgagca aatggcagac tacaacgcgc 400 
tggggatcac cgtgcgttat cttgctttcc cgcgccaggg gctggacagc 450 
gatgcagaga aagaaatgaa agctatctgg tgtgcgaaag ataaaaacaa 500 
agcgtttgat gatgtgatgg caggtaaaag cgtcgcacca gccagttgcg 550 
acgtggatat tgccgaccat tacgcacttg gcgtccagct tggcgttagc 600 
ggtactccgg cagttgtgct gagcaatggc acacttgttc cgggttacca 650 
gccgccgaaa gagatgaaag aatttctcga cgaacaccaa aaaatgacca 700 
gcggtaaagg atcaactagt ggttctggtc atcaccatca ccatcactcc 750 
gcgggtctgg tgccacgcgg tagttgtacc acgactcaca cctttgtcaa 800 
ggcgctgacc atggatggca agcaggctgc ctggcggttt atccggatag 850 
atacggcctg t  
 
5. NA SEQ 5 
Description: Coding sequence for DsbC-NL4-10K 
Sequence: 
atgaagaaag gttttatgtt gtttactttg ttagcggcgt tttcaggctt  50 
tgctcaggct gatgacgcgg caattcaaca aacgttagcc aaaatgggca 100 
tcaaaagcag cgatattcag cccgcgcctg tagctggcat gaagacagtt 150 
ctgactaaca gcggcgtgtt gtacatcacc gatgatggta aacatatcat 200 
tcaggggcca atgtatgacg ttagtggcac ggctccggtc aatgtcacca 250 
ataagatgct gttaaagcag ttgaatgcgc ttgaaaaaga gatgatcgtt 300 
tataaagcgc cgcaggaaaa acacgtcatc accgtgttta ctgatattac 350 
ctgtggttac tgccacaaac tgcatgagca aatggcagac tacaacgcgc 400 
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tggggatcac cgtgcgttat cttgctttcc cgcgccaggg gctggacagc 450 
gatgcagaga aagaaatgaa agctatctgg tgtgcgaaag ataaaaacaa 500 
agcgtttgat gatgtgatgg caggtaaaag cgtcgcacca gccagttgcg 550 
acgtggatat tgccgaccat tacgcacttg gcgtccagct tggcgttagc 600 
ggtactccgg cagttgtgct gagcaatggc acacttgttc cgggttacca 650 
gccgccgaaa gagatgaaag aatttctcga cgaacaccaa aaaatgacca 700 
gcggtaaagg atcaactagt ggttctggtc atcaccatca ccatcactcc 750 
gcgggtctgg tgccacgcgg tagttgtacc acgactcaca cctttgtcaa 800 
ggcgctgacc atggatggca agcaggctgc ctggcggttt atccggatag 850 
atacggcctg taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 
